var docs;if (!docs) docs =[]; docs["27"]={"2701":"<p><b>Title</b> Alpha1-Blockers / Beta-Blockers</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Clinical severity of this interaction may be at least somewhat reduced with ophthalmic products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products. <b>Severity</b> Moderate <b>Onset</b> Immediate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Exercise caution if an alpha<sub>1</sub>-blocker is added to existing beta-blocker therapy. Monitor for hypotension during first few days of concomitant therapy. A priori reduction in alpha<sub>1</sub>-blocker (especially systemic) dose may be warranted. Administering the first dose of systemic agents at bedtime may help minimize risk of severe hypotension. The risk associated with the use of ophthalmic products in either interacting group is probably less than that associated with systemic agents. If the alpha<sub>1</sub>-blocker is being used to treat BPH, consider using tamsulosin since its alpha<sub>1</sub>-A selectivity is least likely to cause hypotension.</p>\n<div>\n <p><b>Alpha1-Blockers Interacting Members</b> Alfuzosin*, Doxazosin, Indoramin, Moxisylyte, Naftopidil, Nicergoline, Phenoxybenzamine, Phentolamine, Prazosin*, Silodosin, Tamsulosin, Terazosin</p>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol*, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Metoprolol, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)<br><b>Exceptions</b> Levobunolol, Metipranolol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Hypotension, as a first-dose response to prazosin, is exacerbated by beta-blocker therapy.<sup>1,2</sup> Normal hemodynamic compensation for prazosin-induced hypotension (increased heart rate and cardiac output) is seemingly blunted by beta-blocker therapy. The body may overcome this problem within a few hours/days. The AUC of alfuzosin (2.5 mg single dose) was increased 21% in 8 normal subjects when administered with atenolol (100 mg single dose).<sup>3</sup> The AUC of atenolol was increased 14%. Significant reductions in mean blood pressure and mean heart rate were reported. These pharmacodynamic changes were likely due to additive effects of the individual agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Seideman P, Grahnen A, Haglund K, et al, “Prazosin First Dose Phenomenon During Combined Treatment With a Beta-Adrenoreceptor in Hypertensive Patients,” <i>Br J Clin Pharmacol</i>, 1982, 13(6):865-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7093116\">[PubMed 7093116]</a></p>\n<p>2. Elliott HL, McLean K, Sumner DJ, et al, “Immediate Cardiovascular Responses to Oral Prazosin-Effects of Concurrent Beta-Blockers,” <i>Clin Pharmacol Ther</i>, 1981, 29(3):303-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6110503\">[PubMed 6110503]</a></p>\n<p>3. Prescribing information. Uroxatral (alfuzosin). Bridgewater, NJ: sanofi-aventis U.S. LLC, 10/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2702":"<p><b>Title</b> Sulfonylureas / Beta-Blockers</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Clinical severity of this interaction may be at least somewhat reduced with opthalmic products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Closely monitor blood glucose levels because beta-blockers may decrease the efficacy of sulfonylurea-type medications. Cardioselective beta-blockers (e.g., atenolol, metoprolol) may be less likely to interact or may have less of an effect on sulfonylurea response. Note that cardioselectivity is diminished at increasing doses. Instruct patients that tachycardia, as a sign of hypoglycemia, may not be present. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol*, Arotinolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Metoprolol, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol*, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)<br><b>Exceptions</b> Levobunolol, Metipranolol</p>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE*, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE*, TOLAZamide, TOLBUTamide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Data demonstrates varying, and conflicting, effects of beta-blockers on sulfonylurea activity. Some agents may inhibit beta-2 receptor-mediated sulfonylurea-induced insulin release from the pancreas. The use of beta-blockers in diabetic patients has been associated with an increased risk of hyperglycemia, hypoglycemia, and hypertension.<sup>1,2,3,4</sup> One particular study evaluating the impact of beta-blocker therapy on sulfonylurea response found evidence that concurrent use of a beta-blocker (acebutolol 400 mg or propranolol 160 mg) with glibenclamide 5 mg (i.e., glyburide) was associated with an increase blood glucose AUC (i.e., reduced sulfonylurea effect) vs. glibenclamide alone.<sup>3</sup> Of note, the impact of the cardioselective acebutolol appeared to be somewhat less than that of the non-selective propranolol.<br><br>Beta-blockers have been shown to inhibit the release of insulin when blood glucose is high and inhibit gluconeogenesis when blood glucose levels are low. In addition, nonselective beta-blockers may increase blood pressure due to inhibition of both beta-1 and beta-2 receptors leading to vasoconstriction from unopposed alpha-receptor stimulation.<sup>5,6</sup> However, conflicting data show propranolol does not inhibit the actions of sulfonylurea medications.<sup>7,8,9</sup> Furthermore, recent studies reveal cardiovascular benefits of beta-blocker use in diabetic patients but recommend the use of a cardioselective agent if a beta-blocker is indicated.<sup>5,10</sup><br><br>Tachycardia, as a sign of hypoglycemia induced by epinephrine release, is also likely masked by beta-blockers.<sup>11,12,13</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Skarfors ET, Lithell HO, Selinus I, et al, “Do Antihypertensive Drugs Precipitate Diabetes in Predisposed Men?” <i>BMJ</i>, 1989, 298:1147-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2500168\">[PubMed 2500168]</a></p>\n<p>2. Mykkanen L, Kuusisto J, Pyorala K, et al, “Increased Risk of Non-Insulin-Dependent Diabetes Mellitus in Elderly Hypertensive Subjects,” <i>J Hypertens</i>, 1994, 12:1425-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7706704\">[PubMed 7706704]</a> </p>\n<p>3. Zaman R, Kendall MJ, Biggs PI, “The Effect of Acebutolol and Propranolol on the Hypoglycaemic Action of Glibenclamide,” <i>Br J Clin Pharmacol</i>, 1982, 13 (4):507-12.3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6802160\">[PubMed 6802160]</a></p>\n<p>4. “The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V),” <i>Arch Intern Med</i>, 1993, 153:154-182. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8422206\">[PubMed 8422206]</a></p>\n<p>5. Cruickshank JM, “Beta-Blockers Continue to Surprise Us,” <i>Europ Heart J</i>, 2000, 23:354-364. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10666349\">[PubMed 10666349]</a></p>\n<p>6. McMurtry RJ, “Propranolol, Hypoglycemia, and Hypertensive Crisis,” <i>Ann Intern Med</i>, 1974, 80:669-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4823826\">[PubMed 4823826]</a></p>\n<p>7. Groop L and Totterman KJ, “Propranolol Does Not Inhibit Sulphonylurea-Stimulated Insulin Secretion in Patients with Non-Insulin Dependent Diabetes Mellitus,” <i>Acta Endo</i>, 1982, 100:410-415. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7051722\">[PubMed 7051722]</a></p>\n<p>8. Thamer M, et al, “Association Between Antihypertensive Drug Use and Hypoglycemia: A Case-Control Study of Diabetic Users of Insulin or Sulfonylureas,” <i>Clin Ther</i>, 1999, 21 (8):1387-1400. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10485510\">[PubMed 10485510]</a></p>\n<p>9. Shorr RI, Ray WA, Daugherty JR, et al, “Antihypertensives and the Risk of Serious Hypoglycemia in Older Persons Using Insulin or Sulfonylureas,” <i>JAMA</i>, 1997, 278 (19):40-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9207336\">[PubMed 9207336]</a></p>\n<p>10. Cruickshank JM, “Beta-blockers and Diabetes: The Bad Guys Come Good,” <i>Cardiovasc Drugs Ther</i>, 2002, 16:457-470. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12652116\">[PubMed 12652116]</a></p>\n<p>11. Deacon SP, Karuananayake A, and Barnett D, “Acebutolol, Atenolol, and Propranolol and Metabolic Responses to Acute Hypoglycaemia in Diabetics,” <i>Br Med J</i>, 1977, 2(6097):1255-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=338101\">[PubMed 338101]</a></p>\n<p>12. Deacon SP and Barnett D, “Comparison of Atenolol and Propranolol During Insulin-Induced Hypoglycaemia,” <i>Br Med J</i>, 1976, 2(6030):272-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8184\">[PubMed 8184]</a></p>\n<p>13. Ostman J, Arner P, Haglund K, et al, “Effect of Metoprolol and Alprenolol on the Metabolic, Hormonal, and Haemodynamic Response to Insulin-Induced Hypoglycaemia in Hypertensive, Insulin-Dependent Diabetics,” <i>Acta Med Scand</i>, 1982, 211(5):381-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7051762\">[PubMed 7051762]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2703":"<p><b>Title</b> Glucagon / Beta-Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Beta-Blockers may diminish the hyperglycemic effect of Glucagon. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required. Ophthalmic beta-blockers would not be expected to affect glucagon.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Metoprolol, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol*, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)<br><b>Exceptions</b> Levobunolol, Metipranolol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Limited data suggests that the hyperglycemic actions of glucagon are reduced in the presence of propranolol.<sup>1</sup> The mechanism is unknown. Possible causes include inhibition of the catecholamines released in response to glucagon, or reduced gluconeogenesis.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Messerli FH, Kuchel O, Tolis G, et al, “Effects of Beta-Adrenergic Blockade on Plasma Cyclic AMP and Blood Sugar Responses to Glucagon and Isoproterenol in Man,” <i>Int J Clin Pharmacol Biopharm</i>, 1976, 14(3):189-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=187546\">[PubMed 187546]</a></p>\n<p>2. Mills GA and Horn JR, “Beta-Blockers and Glucose Control,” <i>Drug Intell Clin Pharm</i>, 1985, 19(4):246-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2861072\">[PubMed 2861072]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2704":"<p><b>Title</b> Beta-Blockers / Nonsteroidal Anti-Inflammatory Agents</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Clinical severity of this interaction is likely to be at least somewhat reduced with ophthalmic products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increases in blood pressure if a nonsteroidal anti-inflammatory agent (NSAID) is initiated/dose increased, or decreases in blood pressure if a NSAID is discontinued/dose decreased; this is particularly important if NSAID treatment is for extended periods of time. Ophthalmic beta-blockers are likely of little concern.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol*, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Metoprolol, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol*, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)<br><b>Exceptions</b> Levobunolol, Metipranolol</p>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen*, Ibuprofen (Topical), Indomethacin*, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen*, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic)*, Piroxicam (Topical), Propyphenazone, Sulindac*, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Indomethacin administration alone can result in increased blood pressure.<sup>1</sup> As such it has the potential to diminish the hypotensive response to beta-blockers.<sup>2,3,4,5</sup> Piroxicam and naproxen also appear to oppose beta-blocker reductions in blood pressure.<sup>6</sup> Sulindac appears least likely to affect the antihypertensive therapy.<sup>5,6</sup> Short-term courses of nonsteroidal anti-inflammatory agent therapy are likely of little concern.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Barrientos A, Alcazar V, Ruilope L, et al, “Indomethacin and Beta-Blockers in Hypertension,” <i>Lancet</i>, 1978, 1(8058):277. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=74701\">[PubMed 74701]</a></p>\n<p>2. Ylitalo P, Pitkajarvi T, Pyykonen ML, et al, “Inhibition of Prostaglandin Synthesis by Indomethacin Interacts With the Antihypertensive Effect of Atenolol,” <i>Clin Pharmacol Ther</i>, 1985, 38(4):443-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3899459\">[PubMed 3899459]</a></p>\n<p>3. Salvetti A, Arzilli F, Pedrinelli R, et al, “Interaction Between Oxprenolol and Indomethacin on Blood Pressure in Essential Hypertensive Patients,” <i>Eur J Clin Pharmacol</i>, 1982, 22(3):197-201. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7049707\">[PubMed 7049707]</a></p>\n<p>4. Watkins J, Abbott EC, Hensby CN, et al, “Attenuation of Hypotensive Effects of Propranolol and Thiazide Diuretics By Indomethacin,” <i>Br Med J</i>, 1980, 281(6242):702-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7427409\">[PubMed 7427409]</a></p>\n<p>5. Abate MA, Neely JL, Layne RD, et al, “Interaction of Indomethacin and Sulindac With Labetalol,” <i>Br J Clin Pharmacol</i>, 1991, 31(3):363-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2054279\">[PubMed 2054279]</a></p>\n<p>6. Chalmers JP, West MJ, Wing LM, et al, “Effects of Indomethacin, Sulindac, Naproxen, Aspirin, and Paracetamol in Treated Hypertensive Patients,” <i>Clin Exp Hypertens A</i>, 1984, 6(6):1077-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6378437\">[PubMed 6378437]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2705":"<p><b>Title</b> Acetaminophen / Cholestyramine Resin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cholestyramine Resin may decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for diminished acetaminophen effects if cholestyramine is used concomitantly. Separate dosing by at least 1 hour to reduce extent of interaction.</p> \n<p><b>Discussion</b> Acetaminophen absorption was reduced by 30% to 98% at 2 hours after concomitant administration with cholestyramine in 4 healthy subjects. Absorption was reduced by only 16% when cholestyramine was administered 1 hour after acetaminophen.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Dordoni B, Willson RA, Thompson RP, et al, “Reduction of Absorption of Paracetamol by Activated Charcoal and Cholestyramine: A Possible Therapeutic Measure,” <i>Br Med J</i>, 1973, 3(5871):86-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4717848\">[PubMed 4717848]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2706":"<p><b>Title</b> Acetaminophen / Barbiturates</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Patients receiving higher doses (and longer duration) of acetaminophen may be at higher risk for experiencing a clinically significant interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Barbiturates may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased effects of acetaminophen, and hepatotoxicity (due to increased concentrations of acetaminophen metabolites), if barbiturates are used concomitantly. This is of particular concern in patients receiving high-dose and/or chronic acetaminophen therapy.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> PHENobarbital, Primidone<br><b>Exceptions</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, Secobarbital, Thiopental</p>\n</div> \n<p><b>Discussion</b> Anticonvulsants may increase acetaminophen clearance by &gt; 40%.<sup>1,2</sup> This is likely due to barbiturate induction of CYP isoenzymes and UDPGTase, leading to increased acetaminophen metabolism. Acetaminophen-induced hepatotoxicity may be enhanced by anticonvulsants due to increased production of toxic acetaminophen metabolites which exceed glutathione binding capacity (the mechanism by which the metabolites are cleared). Acetaminophen concentrations may be relatively low, complicating the diagnosis and delaying the appropriate administration of acetylcysteine.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Perucca E and Richens A, “Paracetamol Disposition in Normal Subjects and in Patients Treated With Antiepileptic Drugs,” <i>Br J Clin Pharmacol</i>, 1979, 7(2):201-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=760753\">[PubMed 760753]</a></p>\n<p>2. Miners JO, Attwood J, and Birkett DJ, “Determinants of Acetaminophen Metabolism: Effect of Inducers and Inhibitors of Drug Metabolism on Acetaminophen's Metabolic Pathways,” <i>Clin Pharmacol Ther</i>, 1984, 35(4):480-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6705446\">[PubMed 6705446]</a></p>\n<p>3. Minton NA, Henry JA, and Frankel RJ, “Fatal Paracetamol Poisoning in an Epileptic,” <i>Hum Toxicol</i>, 1988, 7(1):33-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3346037\">[PubMed 3346037]</a></p>\n<p>4. McClements BM, Hyland M, Callender ME, et al, “Management of Paracetamol Poisoning Complicated by Enzyme Induction Due to Alcohol or Drugs,” <i>Lancet</i>, 1990, 335(8704):1526. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1972451\">[PubMed 1972451]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2708":"<p><b>Title</b> Acetaminophen / CarBAMazepine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Patients receiving higher doses (and longer duration) of acetaminophen may be at higher risk for experiencing a clinically significant interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased effects of acetaminophen, and hepatotoxicity (due to increased concentrations of acetaminophen metabolites), if carbamazepine is used concomitantly. This is of particular concern in patients receiving high-dose and/or chronic acetaminophen therapy.</p> \n<p><b>Discussion</b> Anticonvulsants may increase acetaminophen clearance by &gt;40%.<sup>1,2</sup> This is likely due to carbamazepine induction of CYP isoenzymes and UDPGTase leading to acetaminophen metabolism. Acetaminophen-induced hepatotoxicity may be enhanced by anticonvulsants due to increased production of toxic acetaminophen metabolites which exceed glutathione binding capacity (the mechanism by which the metabolites are cleared). Acetaminophen concentrations may be relatively low, complicating the diagnosis and delaying the appropriate administration of acetylcysteine. This has been demonstrated with phenobarbital and phenytoin.<sup>3,4</sup> Carbamazepine concentrations do not appear to be affected by acetaminophen.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Perucca E and Richens A, “Paracetamol Disposition in Normal Subjects and in Patients Treated With Antiepileptic Drugs,” <i>Br J Clin Pharmacol</i>, 1979, 7(2):201-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=760753\">[PubMed 760753]</a></p>\n<p>2. Miners JO, Attwood J, and Birkett DJ, “Determinants of Acetaminophen Metabolism: Effect of Inducers and Inhibitors of Drug Metabolism on Acetaminophen's Metabolic Pathways,” <i>Clin Pharmacol Ther</i>, 1984, 35(4):480-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6705446\">[PubMed 6705446]</a></p>\n<p>3. Minton NA, Henry JA, and Frankel RJ, “Fatal Paracetamol Poisoning in an Epileptic,” <i>Hum Toxicol</i>, 1988, 7(1):33-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3346037\">[PubMed 3346037]</a></p>\n<p>4. McClements BM, Hyland M, Callender ME, et al, “Management of Paracetamol Poisoning Complicated by Enzyme Induction Due to Alcohol or Drugs,” <i>Lancet</i>, 1990, 335(8704):1526. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1972451\">[PubMed 1972451]</a></p>\n<p>5. Neuvonen PJ, Lehtovaara R, Bardy A, et al, “Antipyretic Analgesics in Patients on Antiepileptic Drug Therapy,” <i>Eur J Clin Pharmacol</i>, 1979, 15(4):263-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=314381\">[PubMed 314381]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2709":"<p><b>Title</b> Acetaminophen / Isoniazid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Isoniazid may enhance the adverse/toxic effect of Acetaminophen. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for evidence of hepatotoxicity if these two agents are used concomitantly. Use of a different analgesic/antipyretic may be considered (eg, nonsteroidal anti-inflammatory agents, or aspirin).</p> \n<p><b>Discussion</b> Case reports. Patients being treated with isoniazid have developed evidence of liver damage after receiving high, single doses of acetaminophen (3.25-11.5 g), or daily doses as low as 2-6 g. Concomitant use of rifampicin and pyrazinamide may have played a role in some cases.<sup>1,2,3</sup> The mechanism of this interaction is unknown. Supposition that isoniazid may increase the production of toxic acetaminophen metabolites has been somewhat refuted.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Murphy R, Swartz R, and Watkins PB, “Severe Acetaminophen Toxicity in a Patient Receiving Isoniazid,” <i>Ann Intern Med</i>, 1990, 113(10):799-800. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2240884\">[PubMed 2240884]</a></p>\n<p>2. Moulding TS, Redeker AG, and Kanel GC, “Acetaminophen, Isoniazid, and Hepatic Toxicity,” <i>Ann Intern Med</i>, 1991, 114(5):431. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1992890\">[PubMed 1992890]</a></p>\n<p>3. Nolan CM, Sandblom RE, Thummel KE, et al, “Hepatotoxicity Associated With Acetaminophen Usage in Patients Receiving Multiple Drug Therapy For Tuberculosis,” <i>Chest</i>, 1994, 105(2):408-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7508362\">[PubMed 7508362]</a></p>\n<p>4. Epstein MM, Nelson SD, Slattery JT, et al, “Inhibition of the Metabolism of Paracetamol by Isoniazid,” <i>Br J Clin Pharmacol</i>, 1991, 31(2):139-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2049229\">[PubMed 2049229]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2710":"<p><b>Title</b> Acetaminophen / Sulfinpyrazone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Sulfinpyrazone may increase the metabolism of Acetaminophen. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action necessary.</p> \n<p><b>Discussion</b> Sulfinpyrazone has been noted to increase acetaminophen clearance by approximately 23%, presumably due to increased glucuronidation (ie, detoxifying pathway).<sup>1</sup> It is doubtful that any reduced clinical response to acetaminophen would be appreciated. Suggestions that the risk of acetaminophen-induced hepatotoxicity have not been validated in the literature.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Miners JO, Attwood J, and Birkett DJ, “Determinants of Acetaminophen Metabolism: Effect of Inducers and Inhibitors of Drug Metabolism on Acetaminophen's Metabolic Pathways,” <i>Clin Pharmacol Ther</i>, 1984, 35(4):480-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6705446\">[PubMed 6705446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2711":"<p><b>Title</b> Acetaminophen / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> RifAMPin may increase the metabolism of Acetaminophen. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of acetaminophen when used with rifampin. Though rifampin may induce acetaminophen glucuronidation (and thus provide a “protective” effect against acetaminophen-induced hepatotoxicity), both agents possess hepatotoxic potential, and therefore, should be considered in a patient monitoring plan.</p> \n<p><b>Discussion</b> Case reports. Clearance of acetaminophen was increased in 2 patients receiving rifampin 600 mg/day.<sup>1</sup> Rifampin is stated to induce the glucuronidation of acetaminophen (ie, the detoxification pathway) without evidence that oxidation is induced. Acetaminophen efficacy might be decreased. Both acetaminophen and rifampin, however, possess hepatotoxic potential. Such should also be considered during concomitant therapy as it's unclear whether the rifampin-induced glucuronidation is ample to outweigh their independent hepatotoxic potential.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescott LF, Critchley JA, Balali-Mood M, et al, “Effects of Microsomal Enzyme Induction on Paracetamol Metabolism in Man,” <i>Br J Clin Pharmacol</i>, 1981, 12(2):149-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7306429\">[PubMed 7306429]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2712":"<p><b>Title</b> Sulfonylureas / Fibric Acid Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fibric Acid Derivatives may enhance the hypoglycemic effect of Sulfonylureas. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects of sulfonylureas and signs of hypoglycemia if a fibric acid derivative is initiated/dose increased, or decreased effects if a fibric acid derivative is discontinued/dose decreased. Populations at high risk of hypoglycemia, such as the elderly or those with a history of hypoglycemic events, may warrant further education on hypoglycemia and/or closer monitoring.</p>\n<div>\n <p><b>Fibric Acid Derivatives Interacting Members</b> Bezafibrate, Ciprofibrate, Fenofibrate and Derivatives, Gemfibrozil*</p>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE*, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE*, TOLAZamide, TOLBUTamide*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Concurrent use of gemfibrozil or fenofibrate with glyburide was associated with an increased odds of severe hypoglycemia (i.e., requiring hospitalization or emergency department treatment) in patients receiving the sulfonylurea glyburide (OR=1.57 and 1.84, respectively), according to a case-control study of sulfonylurea users.<sup>1</sup> While these findings were specific to glyburide, there was also a smaller and non-significant increase in odds for severe hypoglycemia with the concurrent use of glipizide with either gemfibrozil or fenofibrate. Prior published case reports similarly describe hypoglycemia with the use of clofibrate and sulfonylureas.<sup>2,3</sup> Another case report describes a patient on glyburide (5 mg/day) who developed hypoglycemia when started on gemfibrozil (1200 mg/day), which is an outcome that recurred on rechallenge.<sup>4</sup> <br><br>The mechanism for this apparent interaction is uncertain but has been suggested to possibly involve OATP inhibition and/or displacement of sulfonylurea from plasma proteins, as both fibrates and sulfonylureas are highly protein bound. Pharmacodynamically, fibrates may affect insulin secretion, and clofibrate might play a role in decreasing insulin resistance, and/or altering the renal excretion of sulfonylureas that may theoretically potentiate the hypoglycemic effect of sulfonylureas. It is unlikely that interaction is the result of fibrate-mediated inhibition of sulfonylurea metabolism, as in vitro studies predict less than a 10% increase in glyburide AUC with fenofibrate and gemfibrozil.<sup>1</sup> These in vitro findings are consistent with one small study in healthy volunteers (n=10) that reported only an average 23% increase in glimepiride AUC when a single dose of glimepiride (0.5 mg) was administered following a 2-day course of gemfibrozil (600 mg twice daily).<sup>5</sup> No significant clinical effects were noted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Schelleman H, Han X, Brensinger CM, et al. Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. <i>Br J Clin Pharmacol</i>. 2014; Feb 18 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24548191\">[PubMed 24548191]</a></p>\n<p>2. Petitpierre B, Perrin L, Rudhardt M, et al. Behavior of chlorpropamide in renal insufficiency and under the effect of associated drug therapy. <i>Int J Clin Pharmacol</i>. 1972;6(2):120-124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4638970\">[PubMed 4638970]</a></p>\n<p>3. Ferrari C, Frezzati S, Testori GP, et al. Potentiation of hypoglycaemic response to intravenous tolbutamide by clofibrate. <i>N Engl J Med</i>. 1976;294(21):1184. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1264124\">[PubMed 1264124]</a></p>\n<p>4. Ahmad S. Gemfibrozil: interaction with glyburide. <i>South Med J</i>. 1991;84(1):102. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1898783\">[PubMed 1898783]</a></p>\n<p>5. Niemi M, Neuvonen PJ, Kivisto KT. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. <i>Clin Pharmacol Ther</i>. 2001;70(5):439-445. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11719730\">[PubMed 11719730]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2714":"<p><b>Title</b> Sulfonylureas / Chloramphenicol (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Chloramphenicol (Systemic) may decrease the metabolism of Sulfonylureas. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects of sulfonylureas if chloramphenicol is initiated/dose increased, or decreased effects if chloramphenicol is discontinued/dose decreased.</p>\n<div>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE*, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, TOLAZamide, TOLBUTamide*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Chloramphenicol has been demonstrated to double the serum concentrations of tolbutamide, and double the half-life of chlorpropamide, resulting in hypoglycemia.<sup>1,2,3</sup> The mechanism of these interactions is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Christensen LK and Skovsted L, “Inhibition of Drug Metabolism by Chloramphenicol,” <i>Lancet</i>, 1969, 2(7635):1397-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4188280\">[PubMed 4188280]</a></p>\n<p>2. Petitpierre B, Perrin L, Rudhardt M, et al, “Behavior of Chlorpropamide in Renal Insufficiency and Under the Effect of Associated Drug Therapy,” <i>Int J Clin Pharmacol</i>, 1972, 6(2):120-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4638970\">[PubMed 4638970]</a></p>\n<p>3. Brunova E, Slabochova Z, Platilova H, et al, “Interaction of Tolbutamide and Chloramphenicol in Diabetic Patients,” <i>Int J Clin Pharmacol Biopharm</i>, 1977, 15(1):7-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=838527\">[PubMed 838527]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2715":"<p><b>Title</b> Sulfonylureas / Cholestyramine Resin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cholestyramine Resin may decrease the absorption of Sulfonylureas. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased effects of sulfonylureas if these two agents are used concomitantly.</p>\n<div>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE, Gliclazide, Glimepiride, GlipiZIDE*, GlyBURIDE, TOLAZamide<br><b>Exception</b> TOLBUTamide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Small study demonstrated a 29% reduction (average) in glipizide absorption caused by cholestyramine.<sup>1</sup> This is presumably due to intragut binding of glipizide to cholestyramine. The clinical significance of this interaction appears low. Tolbutamide absorption does not appear to be affected by cholestyramine.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kivisto KT and Neuvonen PJ, “The Effect of Cholestyramine and Activated Charcoal on Glipizide Absorption,” <i>Br J Clin Pharmacol</i>, 1990, 30(5):733-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2271372\">[PubMed 2271372]</a></p>\n<p>2. Hunninghake DB and Pollack EW, “Effect of Bile Acid Sequestering Agents on the Absorption of Aspirin, Tolbutamide, and Warfarin,” <i>Fed Proc</i>, 1977, 35:996.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2716":"<p><b>Title</b> Sulfonylureas / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Sulfonylureas. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Seek alternatives to these combinations when possible. Monitor closely for diminished therapeutic effects of sulfonylureas if rifampin is initiated/dose increased, or enhanced effects if rifampin is discontinued/dose decreased.</p>\n<div>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE*, TOLAZamide, TOLBUTamide*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A number of reports describe significant reductions in the half-life, serum concentrations, and clinical effects of tolbutamide upon addition of rifampin to the regimen.<sup>1,2,3,4</sup> The AUC of gliclazide (80 mg single dose) was decreased approximately 70% in 9 normal subjects when administered following a 6-day course of rifampin (600 mg/day).<sup>5</sup> At least one available case report involving glyburide, and a small study with both glipizide and glyburide, report reduced sulfonylurea concentrations.<sup>6,7</sup> The hypoglycemic effects of glyburide were noted to decrease approximately 40%. Microsomal enzyme induction (CYP2C9) by rifampin is the likely cause of these effects. The effects on other agents in the class might be similar.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Syvalahti EK, Pihlajamaki KK, and Iisalo EJ, “Rifampicin and Drug Metabolism,” <i>Lancet</i>, 1974, 2(7874):232-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4135664\">[PubMed 4135664]</a></p>\n<p>2. Zilly W, Breimer DD, and Richter E, “Stimulation of Drug Metabolism by Rifampicin in Patients With Cirrhosis or Cholestasis Measured by Increased Hexobarbital and Tolbutamide Clearance,” <i>Eur J Clin Pharmacol</i>, 1977, 11(4):287-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=862650\">[PubMed 862650]</a></p>\n<p>3. Zilly W, Breimer DD, and Richter E, “Induction of Drug Metabolism in Man After Rifampicin Treatment Measured by Increased Hexobarbital and Tolbutamide Clearance,” <i>Eur J Clin Pharmacol</i>, 1975, 9(2-3):219-27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1233266\">[PubMed 1233266]</a></p>\n<p>4. Syvalahti E, Pihlajamaki K, and Iisalo E, “Effect of Tuberculostatic Agents on the Response of Serum Growth Hormone and Immunoreactive Insulin to Intravenous Tolbutamide, and on the Half-Life of Tolbutamide,” <i>Int J Clin Pharmacol Biopharm</i>, 1976, 13(2):83-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1254383\">[PubMed 1254383]</a></p>\n<p>5. Park JY, Kim KA, Park PW, et al, “Effect of Rifampin on the Pharmacokinetics and Pharmacodynamics of Gliclazide,” <i>Clin Pharmacol Ther</i>, 2003, 74(4):334-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14534520\">[PubMed 14534520]</a></p>\n<p>6. Self TH, Tsiu SJ, and Fowler JW Jr, “Interaction of Rifampin and Glyburide,” <i>Chest</i>, 1989, 96(6):1443-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2510976\">[PubMed 2510976]</a></p>\n<p>7. Niemi M, Backman JT, Neuvonen M, et al, “Effects of Rifampin on the Pharmacokinetics and Pharmacodynamics of Glyburide and Glipizide,” <i>Clin Pharmacol Ther</i>, 2001, 69(6):400-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11406737\">[PubMed 11406737]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2717":"<p><b>Title</b> Sulfonylureas / Sulfonamide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sulfonamide Antibiotics may enhance the hypoglycemic effect of Sulfonylureas. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Sulfonamide derivatives may increase the risk of severe hypoglycemic events associated with sulfonylureas. Advise patients about the increased risk for hypoglycemia with this combination, and monitor for increased therapeutic effects of sulfonylureas if a sulfonamide is initiated/dose increased, or decreased effects if a sulfonamide is discontinued/dose decreased.</p>\n<div>\n <p><b>Sulfonamide Antibiotics Interacting Members</b> SulfADIAZINE, Sulfadoxine, Sulfamethoxazole*, SulfiSOXAZOLE*</p>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE*, Gliclazide, Glimepiride, GlipiZIDE*, GlyBURIDE*, TOLAZamide, TOLBUTamide*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> One review of 900 glyburide-treated patients admitted to a hospital due to hypoglycemia discovered that treatment with sulfamethoxazole in the previous week increased the odds of this event by 6-fold.<sup>1</sup> Similarly, a retrospective cohort of 37,086 Medicare patients taking glyburide or glipizide was found a significantly higher risk of emergency room visits due to hypoglycemia among sulfamethoxazole-trimethoprim users than among users of other antibiotics associated with the use of glyburide (OR 3.78, 95% CI: 1.81-7.90) and glipizide (OR 3.89, 95% CI: 2.29-6.60).<sup>2</sup> Comparable results were also found in two case-control and cross-over studies when evaluating whether orally administered antibiotics increase the risk of severe hypoglycemia in glipizide and glyburide users.<sup>3</sup> Numerous published reports also describe hypoglycemic events associated with the concurrent use of sulfamethoxazole-trimethoprim and sulfonylureas.<sup>4,5,6</sup><br><br>Proposed mechanisms for this interaction include inhibition of sulfonylurea metabolism by sulfonamides and/or displacement of sulfonylureas from protein binding sites resulting in increased free concentrations of sulfonylureas.<sup>7</sup> Of these potential mechanisms inhibition of CYP2C9-mediated sulfonylurea metabolism is likely the most responsible, considering both the ability of various sulfonamides to inhibit CYP2C9,<sup>8</sup> and questions raised about the clinical significance of protein binding displacement-related drug interaction.<sup>9,10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug Interactions Among Elderly Patients Hospitalized for Drug Toxicity. <i>JAMA</i>. 2003;289(13):1652-1658. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12672733\">[PubMed 12672733]</a></p>\n<p>2. Tan A, Holmes HM, Kuo YF, Raji MA, Goodwin JS. Coadministration of co-trimoxazole With sulfonylureas: hypoglycemia events and pattern of use. <i>J Gerontol A Biol Sci Med Sci</i>. 2014; May 24 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24858839\">[PubMed 24858839]</a></p>\n<p>3. Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S. Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide. <i>Clin Pharmacol Ther</i>. 2010;88(2):214-222 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20592722\">[PubMed 20592722]</a></p>\n<p>4. Soeldner JS, Steinke J. Hypoglycemia in tolbutamide-treated diabetes: report of two cases with measurement of serum insulin. <i>JAMA</i>. 1965;193:398-399. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14313905\">[PubMed 14313905]</a></p>\n<p>5. Baciewicz AM, Swafford WB. Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole. <i>Drug Intell Clin Pharm</i>. 1984;18(4):309-310. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6609055\">[PubMed 6609055]</a></p>\n<p>6. Johnson JF, Dobmeier ME. Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction. <i>DICP</i>. 1990;24(3):250-251. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2316232\">[PubMed 2316232]</a></p>\n<p>7. Wing LM, Miners JO. Co-trimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulfamethoxazole separately and combined on tolbutamide disposition. <i>Br J Clin Pharmacol</i>. 1985;20(5):482-485. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3878154\">[PubMed 3878154]</a></p>\n<p>8. Komatsu K, Ito K, Nakajima Y, et al. Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. <i>Drug Metab Dispos</i>. 2000;28(4):475-481. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10725317\">[PubMed 10725317]</a></p>\n<p>9. Sellers EM. Plasma protein displacement interactions are rarely of clinical Significance. <i>Pharmacology</i>. 1979;18(5):225-227. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=482342\">[PubMed 482342]</a></p>\n<p>10. Rolan PE. Plasma protein binding displacement interactions--why are they still regarded as clinically important? <i>Br J Clin Pharmacol</i>. 1994;37(2):125-128. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8186058\">[PubMed 8186058]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2718":"<p><b>Title</b> Sulfonylureas / Cyclic Antidepressants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects of sulfonylureas if a cyclic antidepressant is initiated/dose increased, or decreased effects if a cyclic antidepressant is discontinued/dose decreased.</p>\n<div>\n <p><b>Cyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Maprotiline*, Melitracen [INT], Nortriptyline*, Protriptyline, Trimipramine</p>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE*, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE*, TOLAZamide*, TOLBUTamide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case reports describe hypoglycemia possibly due to the following drug combinations: Tolazamide-doxepin; chlorpropamide-nortriptyline; and glyburide/phenformin-maprotiline.<sup>1,2</sup> The patient in the doxepin case was eventually stabilized on a dose of tolazamide that was 10% of that used before the doxepin was initiated.<sup>1</sup> The patient in the maprotiline case was restabilized on 50% of the preglyburide/phenformin dose.<sup>2</sup> One small study showed no effect on the half-life of tolbutamide by amitriptyline.<sup>3</sup> The mechanism of these interactions is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. True BL, Perry PJ, and Burns EA, “Profound Hypoglycemia With the Addition of a Tricyclic Antidepressant to Maintenance Sulfonylurea Therapy,” <i>Am J Psychiatry</i>, 1987, 144(9):1220-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3631324\">[PubMed 3631324]</a></p>\n<p>2. Zogno MG, Tolfo L, and Draghi E, “Hypoglycemia Caused by Maprotiline in a Patient Taking Oral Antidiabetics,” <i>Ann Pharmacother</i>, 1994, 28(3):406. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8193439\">[PubMed 8193439]</a></p>\n<p>3. Pond SM, Graham GG, Birkett DJ, et al, “Effects of Tricyclic Antidepressants on Drug Metabolism,” <i>Clin Pharmacol Ther</i>, 1975, 18(2):191-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=50160\">[PubMed 50160]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2720":"<p><b>Title</b> Methotrexate / Acitretin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Acitretin may enhance the hepatotoxic effect of Methotrexate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of acitretin with methotrexate is contraindicated due to a possible increased risk of hepatotoxicity.</p> \n<p><b>Discussion</b> Due to reports of an increased hepatitis risk with concurrent methotrexate and etretinate, the prescribing information for acitretin also lists concurrent therapy with methotrexate as a contraindication.<sup>1</sup><br><br>The specific mechanism for this possible interaction is uncertain, but both drugs have been independently associated with hepatotoxicity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Soriatane (acitretin). Coral Gables, FL: Stiefel Laboratories, Inc., July 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2721":"<p><b>Title</b> Adenosine / Theophylline Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Theophylline Derivatives may diminish the therapeutic effect of Adenosine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Therapeutic effects of adenosine may be significantly blunted by theophylline. Significantly higher adenosine doses, or alternative agents, may be required. Monitor for decreased therapeutic effects of adenosine if the patient is already receiving a theophylline derivative. Discontinue theophylline derivatives in advance (5 half-lives is specifically recommended) of scheduled diagnostic use of adenosine (e.g., for radionuclide imaging studies) whenever possible.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Dyphylline, Theophylline</p>\n</div> \n<p><b>Discussion</b> Theophylline (like other methylxanthines) appears to antagonize at least some of the receptors with which adenosine interacts.<sup>1,2,3,4,5,6</sup> This is likely to diminish adenosine-induced vasodilation and to potentially oppose other therapeutic activity of adenosine.<sup>5,6</sup><br><br>Consequently, the prescribing information for therapeutic adenosine cautions that higher adenosine doses may be required with concurrent methylxanthines.<sup>5</sup> The prescribing information for diagnostic adenosine recommends that all methylxanthines be withheld for at least 5 half-lives prior to administration of adenosine.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Reyes E, Loong CY, Harbinson M, et al, “High-Dose Adenosine Overcomes the Attenuation of Myocardial Perfusion Reserve Caused by Caffeine,” <i>J Am Coll Cardiol</i>, 2008, 52(24):2008-16. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19055993\">[PubMed 19055993]</a></p>\n<p>2. Smits P, Lenders JW, Thien T, “Caffeine and Theophylline Attenuate Adenosine-Induced Vasodilation in Humans,” <i>Clin Pharmacol Ther</i>, 1990, 48(4):410-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2225701\">[PubMed 2225701]</a></p>\n<p>3. Rongen GA, Brooks SC, Ando S, et al, “Caffeine Abstinence Augments the Systolic Blood Pressure Response to Adenosine in Humans,” <i>Am J Cardiol</i>, 1998, 81(11):1382-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9631984\">[PubMed 9631984]</a></p>\n<p>4. Smits P, Schouten J, and Thien T, “Cardiovascular Effects of Two Xanthines and the Relation to Adenosine Antagonism,” Clin Pharmacol Ther, 1989, 45(6):5939. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2659234\">[PubMed 2659234]</a></p>\n<p>5. Prescribing information. Adenocard (adenosine). Deerfield, IL: Astellas Pharma US, Inc., 11/2009.</p>\n<p>6. Prescribing information. Adenoscan (adenosine). Deerfield, IL: Astellas Pharma US, Inc., 11/2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2722":"<p><b>Title</b> Adenosine / Dipyridamole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dipyridamole may enhance the adverse/toxic effect of Adenosine. Specifically, cardiovascular effects of adenosine may be enhanced. Adenosine dose reduction may be needed. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects of adenosine if the patient is already receiving dipyridamole. Reduction of the initial dose of adenosine may be warranted. According to the 2005 AHA Guidelines for management of supraventricular tachycardia/Reentry SVT, an initial adenosine dose of 3 mg is recommended (instead of 6mg) for patients who are receiving dipyridamole.</p> \n<p><b>Discussion</b> Dipyridamole has been shown to increase the cardiovascular effects of adenosine.<sup>1,2</sup> Asystole has been reported.<sup>3</sup> Such effects might partly be due to an inhibition of adenosine uptake into cells caused by dipyridamole. Effective adenosine doses are thus greatly reduced (up to fourfold in one study).<sup>4</sup> According to the 2005 AHA Guidelines for management of supraventricular tachycardia/Reentry SVT, an initial adenosine dose of 3 mg is recommended (instead of 6 mg) for patients who are receiving dipyridamole.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Biaggioni I, Onrot J, Hollister AS, et al, “Cardiovascular Effects of Adenosine Infusion in Man and Their Modulation by Dipyridamole,” <i>Life Sci</i>, 1986, 39(23):2229-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3537603\">[PubMed 3537603]</a></p>\n<p>2. Conradson TB, Dixon CM, Clarke B, et al, “Cardiovascular Effects of Infused Adenosine in Man: Potentiation by Dipyridamole,” <i>Acta Physiol Scand</i>, 1987, 129(3):387-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3577821\">[PubMed 3577821]</a></p>\n<p>3. McCollam PL, Uber WE, and Van Bakel AB, “Adenosine-Related Ventricular Asystole,” <i>Ann Intern Med</i>, 1993, 118(4):315-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8420457\">[PubMed 8420457]</a></p>\n<p>4. Lerman BB, Wesley RC, and Belardinelli L, “Electrophysiologic Effects of Dipyridamole on Atrioventricular Nodal Conduction and Supraventricular Tachycardia. Role of Endogenous Adenosine,” <i>Circulation</i>, 1989, 80(6):1536-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2598420\">[PubMed 2598420]</a></p>\n<p>5. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 7.3: Management of Symptomatic Bradycardia and Tachycardia. <i>Circulation</i>, 2005, 112:IV-67-IV-77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16314375\">[PubMed 16314375]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2723":"<p><b>Title</b> Albendazole / Praziquantel</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Praziquantel may increase serum concentrations of the active metabolite(s) of Albendazole. Specifically, sulfoxide and sulfone metabolite concentrations may increase. Albendazole may increase the serum concentration of Praziquantel. <b>Severity</b> Minor <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Studies have demonstrated up to 4.5 fold increases in albendazole sulfoxide (active metabolite of albendazole) AUC when administered with praziquantel.<sup>1,2,3,4</sup> Two of these studies also showed up to 2.6 fold increases in praziquantel AUC with coadministration.<sup>1,2</sup> The mechanisms of these interaction are unclear. The clinical significance of the observed pharmacokinetic changes is questionable given that clinical studies to date have not demonstrated any consistent increase in either therapeutic or toxic effects of the drugs.<sup>1,2,3,5,6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Homeida M, Leahy W, Copeland S, et al, “Pharmacokinetic Interaction Between Praziquantel and Albendazole in Sudanese Men,” <i>Ann Trop Med Parasitol</i>, 1994, 88(5):551-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7979646\">[PubMed 7979646]</a></p>\n<p>2. Lima RM, Ferreira MA, de Jesus Ponte Carvalho TM, et al, “Albendazole-Praziquantel Interaction in Healthy Volunteers: Kinetic Disposition, Metabolism and Enantioselectivity,” <i>Br J Clin Pharmacol</i>, 2011, 71(4):528-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21395645\">[PubMed 21395645]</a></p>\n<p>3. Garcia H, Lescano A, Lanchote V, et al, “Pharmacokinetics of Combined Treatment With Praziquantel and Albendazole in Neurocysticercosis,” <i>Br J Clin Pharmacol</i>, 2011. Epub. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21332573\">[PubMed 21332573]</a></p>\n<p>4. Prescribing information. Albenza (albendazole). Research Triangle Park, NC: GlaxoSmithKline, June 2009.</p>\n<p>5. Namwanje H, Kabatereine N, Olsen A, et al, “A Randomised Controlled Clinical Trial on the Safety of Co-Administration of Albendazole, Ivermectin and Praziquantel in Infected Schoolchildren in Uganda,” <i>Trans R Soc Trop Med Hyg</i>, 2011, 105(4):181-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21353271\">[PubMed 21353271]</a></p>\n<p>6. Kaur S, Singhi P, Singhi S, et al, “Combination Therapy With Albendazole and Praziquantel Versus Albendazole Alone in Children With Seizures and Single Lesion Neurocysticercosis: A Randomized, Placebo-Controlled Double Blind Trial,” <i>Pediatr Infect Dis J</i>, 2009, 28(5):403-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19325515\">[PubMed 19325515]</a></p>\n<p>7. Mohamed AE, Yasawy MI, Al Karawi MA, “Combined Albendazole and Praziquantel Versus Albendazole Alone in the Treatment of Hydatid Disease,” <i>Hepatogastroenterology</i>, 1998, 45(23):1690-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9840130\">[PubMed 9840130]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2725":"<p><b>Title</b> Vitamin K Antagonists / Acetaminophen</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Patients taking acetaminophen at higher doses and/or for longer duration may be at greater risk for experiencing a clinically significant interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. This appears most likely with daily acetaminophen doses exceeding 1.3 or 2 g/day for multiple consecutive days. <b>Severity</b> Moderate <b>Onset</b> Delayed (Sequence Important) <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects of anticoagulants if acetaminophen is initiated/dose increased, or decreased effects if acetaminophen is discontinued/dose decreased. This may be of particular concern in patients expected to take, or who have been taking, more than 1.3 to 2 g/day of acetaminophen for for several consecutive days. Advise patients to limit acetaminophen intake to short-term treatment of acute illnesses when possible and to report any regular use to the clinician who is monitoring their anticoagulant therapy. Use for more than 3 consecutive days may warrant additional INR testing.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A case-control study of warfarin-treated patients including cases with an INR of 6 or greater (n=93) and controls with an INR of 1.7 to 3.3 (n=196) found that acetaminophen use was independently associated with the presence of an INR of 6 or greater.<sup>1</sup> The odds were increased more than 10-fold (95% confidence interval: 2.6 to 37.9) among those with acetaminophen intake of more than 9100 mg/week (1.3 g/day). Several prospective, randomized, placebo-controlled studies have also found that acetaminophen may increase the INR in warfarin-treated patients with daily acetaminophen doses of 2 to 4 g/day consumed for 10 to 28 days.<sup>2,3,4,5</sup> Acetaminophen at 4 g/day was associated with average 1.04 to 1.2 unit increases in INR (vs. 0.2 to 0.4 in placebo groups),<sup>2,3</sup> while acetaminophen at 2 to 3 g/day was associated with average INR increases of approximately 0.7 units.<sup>5</sup> These INR increases were observed within 3 to 4 days of acetaminophen initiation.<sup>2,5</sup> On longitudinal study of 171 patients and several published case reports similarly describe increased INR and/or bleeding associated with concurrent use of acetaminophen with warfarin or acenocoumarol.<sup>7,8,9,10,11,12,13,14</sup><br><br>One study examining variability in warfarin dose-requirement, often associated with a greater risk for bleeding, identified concurrent use of acetaminophen as an independent predictor of high dose-variability (i.e., 2-fold or greater difference between lowest and highest weekly warfarin dose).<sup>15</sup><br><br>In contrast, several studies have concluded that there is no significant interaction at usual doses. A pharmacokinetic study of 20 healthy volunteers concluded that acetaminophen 4 g/day for 2 weeks was associated with no significant change in the pharmacokinetics of S- or R-warfarin.<sup>16</sup> Another study in warfarin-treated patients also concluded that there was no evidence of any interaction at acetaminophen doses up to 3 g/day.<sup>17</sup> Several studies have also concluded that, in patients treated with the vitamin K antagonists acenocoumarol or phenprocoumon, usual doses of acetaminophen had no significant impact on anticoagulant effects,<sup>18,19,20</sup> though in one study there was a transient increase in the INR of 0.46 units on day 8 of concurrent therapy (in both 1.5 g/day and 3 g/day acetaminophen groups) but by day 15 there was only an average increase of 0.22 units present, and that increase was limited to the higher-dose (3 g/day) group.<sup>18</sup><br><br>One recent review of this apparent interaction concluded that patients using 2 g/day or more of acetaminophen for 3 or more consecutive days should have their INR tested within 3-5 days of the first acetaminophen dose.<sup>21</sup> It was also recommended that acetaminophen use be considered a possible contributing factor for any otherwise unexplained INR variability. An earlier review of this subject concluded that acetaminophen was still the preferred analgesic and antipyretic for warfarin-treated patients, provided that doses of greater than 1.3 g/day for more than 2 weeks were avoided.<sup>22</sup><br><br>The mechanism of this interaction is unclear, but potential contributing mechanisms have been proposed. One such theory involves enzymatic “shunting” whereby acetaminophen metabolism indirectly leads to decreased warfarin metabolism,<sup>23</sup> though data showing no significant change in S- or R-warfarin pharmacokinetics argues against this theory.<sup>16</sup> Another theory holds that acetaminophen ingestion reduces the concentrations of one or more of the vitamin K-dependent clotting factors, possibly due to irreversible inhibition of vitamin K-dependent carboxylation by the toxic NAPQI metabolite.<sup>24</sup> In support of this theory are several studies finding evidence of reduced clotting factor concentrations in patients exposed to this combination.<sup>3,5,25</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. <i>JAMA</i>. 1998;279(9):657-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9496982\">[PubMed 9496982]</a></p>\n<p>2. Mahe I, Bertrand N, Drouet L, et al. Paracetamol: a haemorrhagic risk factor in patients on warfarin. <i>Br J Clin Pharmacol</i>. 2005;59(3):371-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15752384\">[PubMed 15752384]</a></p>\n<p>3. Mahe I, Bertrand N, Drouet L, et al. Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study. <i>Haematologica</i>. 2006;91(12):1621-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17145598\">[PubMed 17145598]</a></p>\n<p>4. Parra D, Beckey NP, Stevens GR. The effect of acetaminophen on the international normalized ratio in patients stabilized on warfarin therapy. <i>Pharmacotherapy</i>. 2007;27(5):675-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17461702\">[PubMed 17461702]</a></p>\n<p>5. Zhang Q, Bal-dit-Sollier C, Drouet L, et al. Interaction between acetaminophen and warfarin in adults receiving long-term oral anticoagulants: a randomized controlled trial. <i>Eur J Clin Pharmacol</i>. 2011;67(3):309-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21191575\">[PubMed 21191575]</a></p>\n<p>6. Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. <i>Pharmacotherapy</i>. 2007;27(9):1237-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17723077\">[PubMed 17723077]</a></p>\n<p>7. Justice JL, Kline SS. Analgesics and warfarin. A case that brings up questions and cautions. <i>Postgrad Med</i>. 1988;83(5):217-8, 220. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3357860\">[PubMed 3357860]</a></p>\n<p>8. Orme M, Breckenridge A, Cook P. Warfarin and Distalgesic interaction. <i>Br Med J</i>. 1976;1(6003):200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1247776\">[PubMed 1247776]</a></p>\n<p>9. Jones RV. Letter: Warfarin and distalgesic interaction. <i>Br Med J</i>. 1976;1(6007):460. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1252799\">[PubMed 1252799]</a></p>\n<p>10. Bartle WR, Blakely JA. Potentiation of warfarin anticoagulation by acetaminophen. <i>JAMA</i>. 1991;265(10):1260. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1995971\">[PubMed 1995971]</a></p>\n<p>11. Fitzmaurice DA, Murray JA. Potentiation of the anticoagulant effect of warfarin. <i>Postgrad Med J</i>. 1997;73(861):439-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9338037\">[PubMed 9338037]</a></p>\n<p>12. Gebauer MG, Nyfort-Hansen K, Henschke PJ, Gallus AS. Warfarin and acetaminophen interaction. <i>Pharmacotherapy</i>. 2003;23(1):109-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12523469\">[PubMed 12523469]</a></p>\n<p>13. Lee R, Wen A, Berube C. Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer. <i>Am J Health Syst Pharm</i>. 2011;68(9):814-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21515865\">[PubMed 21515865]</a></p>\n<p>14. Bagheri H, Bernhard NB, and Montastruc JL, “Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,” Ann Pharmacother, 1999, 33(4):506. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10332548\">[PubMed 10332548]</a></p>\n<p>15. Marrast L, Evans M, Ozonoff A, Henault LE, Rose AJ. Using highly variable warfarin dosing to identify patients at risk for adverse events. <i>Thromb J</i>. 2011;9:14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21985504\">[PubMed 21985504]</a></p>\n<p>16. Kwan D, Bartle WR, Walker SE. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. <i>J Clin Pharmacol</i>. 1999;39(1):68-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9987702\">[PubMed 9987702]</a></p>\n<p>17. Antlitz AM, Mead JA Jr, Tolentino MA. Potentiation of oral anticoagulant therapy by acetaminophen. <i>Curr Ther Res Clin Exp</i>. 1968;10(10):501-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4971464\">[PubMed 4971464]</a></p>\n<p>18. Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, “Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,” J Thromb Haemost, 2003, 1(4):714-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12871405\">[PubMed 12871405]</a></p>\n<p>19. Fattinger K, Frisullo R, Masche U, Braunschweig S, Meier PJ, Roos M. No clinically relevant drug interaction between paracetamol and phenprocoumon based on a pharmacoepidemiological cohort study in medical inpatients. <i>Eur J Clin Pharmacol</i>. 2002;57(12):863-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11936705\">[PubMed 11936705]</a></p>\n<p>20. van den Bemt PM, Geven LM, Kuitert NA, Risselada A, Brouwers JR. The potential interaction between oral anticoagulants and acetaminophen in everyday practice. <i>Pharm World Sci</i>. 2002;24(5):201-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12426965\">[PubMed 12426965]</a></p>\n<p>21. Lopes RD, Horowitz JD, Garcia DA, Crowther MA, Hylek EM. Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. <i>Blood</i>. 2011;118(24):6269-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21911832\">[PubMed 21911832]</a></p>\n<p>22. Shek KL, Chan LN, Nutescu E. Warfarin-acetaminophen drug interaction revisited. <i>Pharmacotherapy</i>. 1999;19(10):1153-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10512064\">[PubMed 10512064]</a></p>\n<p>23. Lehmann DE. Enzymatic shunting: resolving the acetaminophen-warfarin controversy. <i>Pharmacotherapy</i>. 2000;20(12):1464-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11130219\">[PubMed 11130219]</a></p>\n<p>24. Thijssen HH, Soute BA, Vervoort LM, Claessens JG. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. <i>Thromb Haemost</i>. 2004;92(4):797-802. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15467911\">[PubMed 15467911]</a></p>\n<p>25. Whyte IM, Buckley NA, Reith DM, Goodhew I, Seldon M, Dawson AH. Acetaminophen causes an increased International Normalized Ratio by reducing functional factor VII. <i>Ther Drug Monit</i>. 2000;22(6):742-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11128244\">[PubMed 11128244]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2728":"<p><b>Title</b> Primidone / Carbonic Anhydrase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Primidone. Specifically, osteomalacia and rickets. Carbonic Anhydrase Inhibitors may decrease the serum concentration of Primidone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of primidone if a carbonic anhydrase inhibitor is initiated/dose increased, or increased effects if a carbonic anhydrase inhibitor is discontinued/dose decreased. Monitor for evidence of osteomalacia and rickets if these two agents are used concomitantly.</p>\n<div>\n <p><b>Carbonic Anhydrase Inhibitors Interacting Members</b> AcetaZOLAMIDE*, Dichlorphenamide, MethazolAMIDE, Sulthiame, Topiramate, Zonisamide<br><b>Exceptions</b> Brinzolamide, Dorzolamide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case reports demonstrate decreases in serum primidone concentrations when patients were treated with acetazolamide.<sup>1</sup> Other reports demonstrate no such effect.<sup>2</sup> Case reports involving various anticonvulsants demonstrate hyperchloremic acidosis with high urinary calcium excretion leading to severe osteomalacia and rickets in both adults and children.<sup>2,3,4</sup> The mechanisms of these interactions are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Syversen GB, Morgan JP, Weintraub M, et al, “Acetazolamide-Induced Interference With Primidone Absorption. Case Reports and Metabolic Studies,” <i>Arch Neurol</i>, 1977, 34(2):80-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=836189\">[PubMed 836189]</a></p>\n<p>2. Mallette LE, “Anticonvulsants, Acetazolamide, and Osteomalacia,” <i>N Engl J Med</i>, 1975, 293(13):668. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1152917\">[PubMed 1152917]</a></p>\n<p>3. Matsuda I, Takekoshi Y, Shida N, et al, “Renal Tubular Acidosis and Skeletal Demineralization in Patients on Long-Term Anticonvulsant Therapy,” <i>J Pediatr</i>, 1975, 87(2):202-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=239108\">[PubMed 239108]</a></p>\n<p>4. Mallette LE, “Acetazolamide-Accelerated Anticonvulsant Osteomalacia,” <i>Arch Intern Med</i>, 1977, 137(8):1013-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=879939\">[PubMed 879939]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2729":"<p><b>Title</b> CarBAMazepine / Carbonic Anhydrase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Carbonic Anhydrase Inhibitors may increase the serum concentration of CarBAMazepine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of carbamazepine if a carbonic anhydrase inhibitor is initiated. Discontinue acetazolamide or decrease carbamazepine dosing if problems arise. May need to increase carbamazepine dosage following discontinuation of stabilized carbonic anhydrase inhibitor therapy.</p>\n<div>\n <p><b>Carbonic Anhydrase Inhibitors Interacting Members</b> AcetaZOLAMIDE*, Dichlorphenamide, MethazolAMIDE, Sulthiame, Topiramate, Zonisamide<br><b>Exceptions</b> Brinzolamide, Dorzolamide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several case reports and studies demonstrate increases in carbamazepine concentrations following the initiation of acetazolamide.<sup>1,2</sup> This interaction may be used to enhance epilepsy treatment. The mechanism of this interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. McBride MC, “Serum Carbamazepine Levels Are Increased by Acetazolamide,” <i>Ann Neurol</i>, 1984, 16:393.</p>\n<p>2. Forsythe WI, Owens JR, and Toothill C, “Effectiveness of Acetazolamide in the Treatment of Carbamazepine-Resistant Epilepsy in Children,” <i>Develop Med Child Neurol</i>, 1981, 23(6):761-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6797857\">[PubMed 6797857]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2731":"<p><b>Title</b> Lithium / Loop Diuretics</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Concurrent use of lithium is contraindicated in the UK labeling for bumetanide/amiloride.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Loop Diuretics may decrease the serum concentration of Lithium. Loop Diuretics may increase the serum concentration of Lithium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Increase monitoring of both clinical response to lithium therapy and lithium concentrations when using a loop diuretic. Monitor for both increased and decreased lithium concentrations/effects as both have been reported. Some specific combinations are contraindicated in at least some international labeling.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide*, Ethacrynic Acid, Furosemide*, Torsemide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The furosemide prescribing information cautions against using any diuretic in combination with lithium due to a potential to reduce lithium’s clearance and increase the risk of toxicity,<sup>1</sup> and a few case reports do describe lithium toxicity following the initiation of furosemide or bumetanide.<sup>2,3,4</sup> A study of 10,615 elderly patients, who were continuously receiving lithium, reported a substantial increase in the risk of lithium toxicity within a month of initiating a loop diuretic (RR=5.5, 95% CI 1.9-16.1).<sup>5</sup><br><br>In contrast, data from studies of healthy volunteers and hypertensive patients report no significant change in lithium pharmacokinetics and no signs of toxicity with concurrent use of lithium and a loop diuretic.<sup>6,7,8</sup> In fact, some studies in volunteers (and one in rats) show that furosemide tends to increase the excretion of lithium,<sup>9,10</sup> which, if resulting in any change, would tend to decrease lithium concentrations.<br><br>The specific mechanism of this possible interaction is not clear, but any increase in lithium concentrations may possibly be related to urinary sodium loss caused by the diuretic with subsequent changes in lithium excretion. Any decrease in lithium concentrations may result from impaired lithium reabsorption.<sup>11,12</sup><br><br>The UK labeling for a bumetanide/amiloride combination product lists concurrent use of lithium as contraindicated.<sup>13</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lasix (furosemide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; April 2008.</p>\n<p>2. Hurtig HI, Dyson WL. Letter: Lithium toxicity enhanced by diuresis. <i>N Engl J Med</i>. 1974;290(13):748-749. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4813752\">[PubMed 4813752]</a></p>\n<p>3. Oh TE. Frusemide and lithium toxicity. <i>Anaesth Intensive Care</i>. 1977;5(1):60-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=842818\">[PubMed 842818]</a></p>\n<p>4. Huang LG. Lithium intoxication with coadministration of a loop-diuretic. <i>J Clin Psychopharmacol</i>. 1990;10(3):228. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2115896\">[PubMed 2115896]</a></p>\n<p>5. Juurlink DN, Mamdani MM, Kopp A, Rochon PA, Shulman KI, Redelmeier DA. Drug-induced lithium toxicity in the elderly: a population-based study. <i>J Am Geriatr Soc</i>. 2004;52(5):794-798. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15086664\">[PubMed 15086664]</a></p>\n<p>6. Saffer D, Coppen A. Frusemide: a safe diuretic during lithium therapy? <i>J Affect Disord</i>. 1983;5(4):289-292. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6229559\">[PubMed 6229559]</a></p>\n<p>7. Crabtree BL, Mack JE, Johnson CD, Amyx BC. Comparison of the effects of hydrochlorothiazide and furosemide on lithium disposition. <i>Am J Psychiatry</i>. 1991;148(8):1060-1063. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1853956\">[PubMed 1853956]</a></p>\n<p>8. Jefferson JW, Kalin NH. Serum lithium levels and long-term diuretic use. <i>JAMA</i>. 1979;241(11):1134-1136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=762764\">[PubMed 762764]</a></p>\n<p>9. Atherton JC, Green R, Hughes S, et al. Lithium clearance in man: effects of dietary salt intake, acute changes in extracellular fluid volume, amiloride and frusemide. <i>Clin Sci (Lond)</i>. 1987;73(6):645-651. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3690979\">[PubMed 3690979]</a></p>\n<p>10. Beutler JJ, Boer WH, Koomans HA, Dorhout Mees EJ. Comparative study of the effects of furosemide, ethacrynic acid and bumetanide on the lithium clearance and diluting segment reabsorption in humans. <i>J Pharmacol Exp Ther</i>. 1992;260(2):768-772. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1738122\">[PubMed 1738122]</a></p>\n<p>11. Shirley DG, Walter SJ, Sampson B. A micropuncture study of renal lithium reabsorption: effects of amiloride and furosemide. <i>Am J Physiol</i>. 1992;263(6 Pt 2):F1128-F1133. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1481889\">[PubMed 1481889]</a></p>\n<p>12. Taniguchi J, Shirley DG, Walter SJ, Imai M. Simulation of lithium transport along the thin segments of Henle's loop. <i>Kidney Int</i>. 1993;44(2):337-343. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8377378\">[PubMed 8377378]</a></p>\n<p>13. Bumetanide/amiloride [UK summary of product characteristics]. Egham, Surrey, United Kingdom: Chemidex Pharma Limited; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2732":"<p><b>Title</b> Lithium / Potassium-Sparing Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Potassium-Sparing Diuretics may increase the excretion of Lithium. Decreases in lithium excretion have also been reported. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for changes in serum lithium concentrations/effects if a potassium-sparing diuretic is initiated, discontinued, or changed in dose.</p>\n<div>\n <p><b>Potassium-Sparing Diuretics Interacting Members</b> AMILoride, Eplerenone, Spironolactone*, Triamterene*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Spironolactone has been reported to both increase serum lithium concentrations and have no effect.<sup>1,2</sup> Triamterene is reported to decrease serum lithium concentrations.<sup>3</sup> Clinical importance is probably limited.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Thomsen K and Schou M, “Renal Lithium Excretion in Man,” <i>Am J Physiol</i>, 1968, 215(4):823-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5676383\">[PubMed 5676383]</a></p>\n<p>2. Baer L, Platman SR, Kassir S, et al, “Mechanisms of Renal Lithium Handling and Their Relationship to Mineralocorticoids: A Dissociation Between Sodium and Lithium Ions,” <i>J Psychiat Res</i>, 1971, 8(2):91-105. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5090127\">[PubMed 5090127]</a></p>\n<p>3. Baer L, Platman SR, and Fieve RR, “Lithium Metabolism: Its Electrolyte Actions and Relationship to Aldosterone. Recent Advances in the Psychobiology of the Depressive Illnesses,” Williams, Katz, and Shield, eds, Washington, DC: DHEW Publications, 1972, 49.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2733":"<p><b>Title</b> Lithium / Thiazide and Thiazide-Like Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Thiazide and Thiazide-Like Diuretics may decrease the excretion of Lithium. <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider reducing the dosage of lithium by 50% upon initiation of a thiazide diuretic. Monitor for increased therapeutic/toxic effects of lithium if a thiazide is initiated/dose increased, or decreased effects if an thiazide is discontinued/dose decreased.</p>\n<div>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide*, Chlorthalidone*, Cyclopenthiazide, HydroCHLOROthiazide*, Hydroflumethiazide*, Indapamide*, Methyclothiazide, MetOLazone, Xipamide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Limited data demonstrate increases (approximately 20%) in serum lithium concentrations within 3 days of hydrochlorothiazide initiation.<sup>1</sup> Similar results have been demonstrated with bendroflumethiazide, chlorothiazide, chlorthalidone, hydroflumethiazide, and indapamide.<sup>2,3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Jefferson JW and Kalin NH, “Serum Lithium Levels and Long-Term Diuretic Use,” <i>JAMA</i>, 1979, 241(11):1134-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=762764\">[PubMed 762764]</a></p>\n<p>2. Solomon JG, “Lithium Toxicity Precipitated by a Diuretic,” <i>Psychosomatics</i>, 1980, 21(5):425, 429. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=394153\">[PubMed 394153]</a></p>\n<p>3. Hanna ME, Lobao CB, and Stewart JT, “Severe Lithium Toxicity Associated With Indapamide Therapy,” <i>J Clin Psychopharmacol</i>, 1990, 10(5):379-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2124221\">[PubMed 2124221]</a></p>\n<p>4. Petersen V, Hvidt S, Thomsen K, et al, “Effect of Prolonged Thiazide Treatment on Renal Lithium Excretion,” <i>Br Med J</i>, 1974, 3(924):143-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4846274\">[PubMed 4846274]</a></p>\n<p>5. Poust RI, Mallinger AG, Mallinger J, et al, “Effect of Chlorothiazide on the Pharmacokinetics of Lithium in Plasma and Erythrocytes,” <i>Psychopharmacol Commun</i>, 1976, 2(3):273-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=996280\">[PubMed 996280]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2734":"<p><b>Title</b> Amphetamines / Carbonic Anhydrase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Carbonic Anhydrase Inhibitors may decrease the excretion of Amphetamines. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects of amphetamines if a carbonic anhydrase inhibitor is initiated/dose increased, or decreased effects if a carbonic anhydrase inhibitor is discontinued/dose decreased.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n <p><b>Carbonic Anhydrase Inhibitors Interacting Members</b> AcetaZOLAMIDE, Dichlorphenamide, MethazolAMIDE, Sulthiame, Topiramate, Zonisamide<br><b>Exceptions</b> Brinzolamide, Dorzolamide</p>\n</div> \n<p><b>Discussion</b> Alkalinizing the urine can dramatically decrease the excretion of amphetamines; possibly to as little as 3% of original dose over 16 hours.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Beckett AH, Rowland M, and Turner P, “Influence of Urinary pH on Excretion of Amphetamine,” <i>Lancet</i>, 1965, 17:303. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14247879\">[PubMed 14247879]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2735":"<p><b>Title</b> Methenamine / Carbonic Anhydrase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Carbonic Anhydrase Inhibitors may diminish the therapeutic effect of Methenamine. <b>Severity</b> Moderate <b>Onset</b> Immediate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider avoiding the concomitant use of carbonic anhydrase inhibitors and methenamine. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.</p>\n<div>\n <p><b>Carbonic Anhydrase Inhibitors Interacting Members</b> AcetaZOLAMIDE, Dichlorphenamide, MethazolAMIDE, Sulthiame, Topiramate, Zonisamide<br><b>Exceptions</b> Brinzolamide, Dorzolamide</p>\n</div> \n<p><b>Discussion</b> Methenamine is hydrolyzed into its active antimicrobial form, formaldehyde, in acidic urine.<sup>1</sup> Agents that alkalinize the urine (e.g. carbonic anhydrase inhibitors, sodium bicarbonate, and some antacids) could theoretically decrease the efficacy of methenamine by preventing this activation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Urex (methenamine). Wytheville Va: Vatring Pharmaceuticals, Inc., December 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2736":"<p><b>Title</b> QuiNIDine / Carbonic Anhydrase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased toxic effects of quinidine if a carbonic anhydrous inhibitor (CAI) is initiated/dose increased, or decreased effects if a CAI is discontinued/dose decreased.</p>\n<div>\n <p><b>Carbonic Anhydrase Inhibitors Interacting Members</b> AcetaZOLAMIDE*, Dichlorphenamide, MethazolAMIDE, Sulthiame, Topiramate, Zonisamide<br><b>Exceptions</b> Brinzolamide, Dorzolamide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The urinary excretion of quinidine was decreased by approximately 50% in 4 normal subjects due to alkalinizing the urine with acetazolamide (500 mg every 12 hours).<sup>1</sup> In alkaline urine (such as caused by acetazolamide), quinidine is present more in the nonionized more readily reabsorbed form. Other carbonic anhydrase inhibitors would likely have a similar effect on quinidine. Evidence of clinical effects is lacking.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gerhardt RE, Knouss RF, Thyrum PT, et al, “Quinidine Excretion in Aciduria and Alkaluria,” <i>Ann Intern Med</i>, 1969, 71(5):927-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5360313\">[PubMed 5360313]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2737":"<p><b>Title</b> Carbonic Anhydrase Inhibitors / Salicylates</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Risk is likely lower in patients using low-dose aspirin for prevention of cardiovascular events.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. <b>Severity</b> Major <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid these combinations when possible. Dichlorphenamide US prescribing information lists its use with high-dose aspirin as contraindicated. If another combination is used, monitor patients closely for adverse effects. Tachypnea, anorexia, lethargy, and coma have been reported. The risk of these effects is likely reduced in patients receiving low cardioprotective salicylate doses.</p>\n<div>\n <p><b>Carbonic Anhydrase Inhibitors Interacting Members</b> AcetaZOLAMIDE*, Dichlorphenamide*, MethazolAMIDE, Sulthiame, Topiramate, Zonisamide<br><b>Exceptions</b> Brinzolamide, Dorzolamide</p>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin*, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate*, Sodium Salicylate, Triflusal</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Salicylate/carbonic anhydrase inhibitor (CAI) combination therapy has resulted in significant metabolic acidosis in children and adults. Symptoms might include drowsiness, vomiting, hyperventilation, confusion, lethargy, or anorexia, and may take several days or weeks to occur.<sup>1,2</sup> The mechanism of this interaction is unclear. Salicylates may reduce CAI protein binding and decrease CAI excretion by the kidneys. In addition, CAI-induced decreases in plasma pH might result in a higher concentration of nonionized salicylate, which can more readily enter the CNS.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cowan RA, Harnell GG, Lowdell CP, et al, “Metabolic Acidosis Induced by Carbonic Anhydrase Inhibitors and Salicylates in Patients With Normal Renal Function,” <i>Br Med J</i>, 1984, 289(6441):347-8. [PubMed 6432091]</p>\n<p>2. Rousseau P and Fuentevilla-Clifton A, “Acetazolamide and Salicylate Interaction in the Elderly: A Case Report,” <i>J Am Geriatr Soc</i>, 1993, 41(8):868-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8340566\">[PubMed 8340566]</a></p>\n<p>3. Anderson CJ, Kaufman PL, and Sturm RJ, “Toxicity of Combined Therapy With Carbonic Anhydrase Inhibitors and Aspirin,” <i>Am J Ophthalmol</i>, 1978, 86(4):516-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=707596\">[PubMed 707596]</a></p>\n<p>4. Sweeney KR, Chapron DJ, Brandt JL, et al, “Toxic Interaction Between Acetazolamide and Salicylate: Case Reports and a Pharmacokinetic Explanation,” <i>Clin Pharmacol Ther</i>, 1986, 40(5):518-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3769383\">[PubMed 3769383]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2738":"<p><b>Title</b> Digoxin / Beta2-Agonists</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Beta2-Agonists may decrease the serum concentration of Digoxin. Likely not an issue with inhaled products. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Beta2-Agonists Interacting Members</b> Albuterol, Arformoterol, Bambuterol, Fenoterol, Formoterol, Indacaterol, Levalbuterol, Metaproterenol, Olodaterol, Pirbuterol, Ritodrine, Salmeterol, Terbutaline, Tulobuterol, Vilanterol</p>\n</div> \n<p><b>Discussion</b> Intravenous and oral albuterol administration has been shown to decrease serum digoxin concentrations by 16%.<sup>1,2</sup> The mechanism might include a redistribution of digoxin to skeletal muscle.<sup>2</sup> Information regarding clinical effects of this interaction is lacking.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Edner M and Jogestrand T, “Oral Salbutamol Decreases Serum Digoxin Concentration,” <i>Eur J Clin Pharmacol</i>, 1990, 38(2):195-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2338119\">[PubMed 2338119]</a></p>\n<p>2. Edner M, Jogestrand T, and Dahlqvist R, “Effect of Salbutamol on Digoxin Pharmacokinetics,” <i>Eur J Clin Pharmacol</i>, 1992, 42(2):197-201. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1618253\">[PubMed 1618253]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2739":"<p><b>Title</b> Beta-Blockers / Alpha2-Agonists</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Comorbidity</b>: The significance of this interaction may be greater in patients with heart failure. Rilmenidine use with a beta-blocker is specifically not recommended in patients with heart failure.</p></li>\n <li><p><b>Dosage Form</b>: Clinical significance of this interaction is likely lower with ophthalmic beta-blockers.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. <b>Severity</b> Moderate <b>Onset</b> Rapid (Sequence Important) <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Closely monitor heart rate in patients receiving clonidine in combination with beta-blockers. Withdraw the beta-blocker several days before clonidine is gradually withdrawn if possible, and monitor blood pressure closely. Rilmenidine labeling states that concurrent use with beta-blockers in patients with heart failure is not recommended. Specific recommendations for other alpha2-agonists are not available. Ophthalmic beta-blockers likely pose a reduced risk.</p>\n<div>\n <p><b>Alpha2-Agonists Interacting Members</b> Brimonidine (Ophthalmic), CloNIDine*, Dexmedetomidine, GuanFACINE, Lofexidine, Methyldopa, Moxonidine, Rilmenidine, TiZANidine<br><b>Exception</b> Apraclonidine</p>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Metoprolol, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol*, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)<br><b>Exceptions</b> Levobunolol, Metipranolol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several reports describe an enhanced hypertensive response to the withdrawal of clonidine in the presence of beta-blockade.<sup>1,2,3,4</sup> The withdrawal of clonidine is followed by an increase in the concentration of circulating catecholamines (centrally suppressed under clonidine therapy). In the presence of beta2-receptor blockade, the vasoconstrictor properties of the catecholamines are unopposed, resulting in the exaggerated hypertensive response. Nonselective beta-blockers pose a greater risk.<br><br>Clonidine U.S. prescribing information recommends discontinuation of beta blockers several days prior to clonidine withdrawal to reduce the risk of rebound hypertension.<sup>5</sup> Additionally, close monitoring of heart rate during concomitant therapy is recommended based on the potential for both drugs to contribute to sinus node dysfunction or AV node block.<sup>5</sup> Rilmenidine labeling states that concurrent use with beta-blockers in patients with heart failure is not recommended.<sup>6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bailey RR, Neale TJ. Rapid clonidine withdrawal with blood pressure overshoot exaggerated by beta-blockade. <i>Br Med J</i>. 1976;1(6015):942-943. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5169\">[PubMed 5169]</a></p>\n<p>2. Cairns SA, Marshall AJ. Clonidine withdrawal. <i>Lancet</i>. 1976;1(7955):368. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=54780\">[PubMed 54780]</a></p>\n<p>3. Strauss FG, Franklin SS, Lewin AJ, et al. Withdrawal of antihypertensive therapy. Hypertensive crisis in renovascular hypertension. <i>JAMA</i>. 1977;238(16):1734-1736. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=578267\">[PubMed 578267]</a></p>\n<p>4. Vernon C, Sakula A. Fatal rebound hypertension after abrupt withdrawal of clonidine and propranolol. <i>Br J Clin Pract</i>. 1979;33(4):112, 121. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=475954\">[PubMed 475954]</a></p>\n<p>5. Catapres-TTS (clonidine) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; October 2011.</p>\n<p>6. Hyperium (rilmenidine) [prescribing information]. Rio de Janeiro, Brazil: Laboratorios Servier de Brasil Ltda; November 2016.</p>\n<p>7. Hyperium (rilmenidine) [summary of product characteristics]. Cedex, France: Les Laboratoires Servier; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2740":"<p><b>Title</b> Cardiac Glycosides / Beta-Blockers</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: The clinical significance of this interaction is likely somewhat decreased with ophthalmic beta-blockers.</p></li>\n <li><p><b>International labeling</b>: The Canadian labeling for pindolol states that concurrent use of digitalis glycosides should be avoided due to the risk for serious bradycardia or heart block with use of the combination.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patient's heart rate and PR interval closely if this combination is used. Ophthalmic beta-blockers are likely of little concern. The Canadian labeling for pindolol states that concurrent use of digitalis glycosides should be avoided due to the risk for serious bradycardia or heart block with use of the combination.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Metoprolol, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol*, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)<br><b>Exceptions</b> Levobunolol, Metipranolol</p>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The bradycardic effects of beta-blockers and cardiac glycosides may be additive in some patients.<sup>1</sup> Patients with increased serum glycoside concentrations are at increased risk of excessive bradycardia (e.g., digoxin-induced arrhythmias being treated with propranolol).<sup>2</sup> Carvedilol has been reported to increase serum digoxin, but not digitoxin, concentrations.<sup>3,4</sup> The clinical effect of this change is small. Acebutolol and sotalol do not appear to have the same pharmacokinetic effect.<sup>5,6</sup><br><br>The Canadian labeling for pindolol states that concurrent use of digitalis glycosides should be avoided due to the risk for serious bradycardia or heart block with use of the combination.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. LeWinter MM, Crawford MH, O'Rourke RA, Karliner JS. The effects of oral propranolol, digoxin and combination therapy on the resting and exercise electrocardiogram. <i>Am Heart J</i>. 1977;93(2):202-209. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=319642\">[PubMed 319642]</a></p>\n<p>2. Turner JR. Propranolol in the treatment of digitalis-induced and digitalis-resistant tachycardias. <i>Am J Cardiol</i>. 1966;18(3):450-457. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5922889\">[PubMed 5922889]</a></p>\n<p>3. De Mey C, Brendel E, Enterling D. Carvedilol increases the systemic bioavailability of oral digoxin. <i>Br J Clin Pharmacol</i>. 1990;29(4):486-490. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1970265\">[PubMed 1970265]</a></p>\n<p>4. Harder S, Brei R, Caspary S, Merz PG. Lack of a pharmacokinetic interaction between carvedilol and digitoxin or phenprocoumon. <i>Eur J Clin Pharmacol</i>. 1993;44(6):583-586. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8405017\">[PubMed 8405017]</a></p>\n<p>5. Ryan JR. Clinical pharmacology of acebutolol. <i>Am Heart J</i>. 1985;109(5 Pt 2):1131-1136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2859776\">[PubMed 2859776]</a></p>\n<p>6. Singh S, Saini RK, DiMarco J, Kluger J, Gold R, Chen YW. Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. The Sotalol Study Group. <i>Am J Cardiol</i>. 1991;68(11):1227-1230. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1951086\">[PubMed 1951086]</a></p>\n<p>7. Visken (pindolol) [prescribing information]. London, Ontario, Canada: Tribute Pharmaceuticals Canada Inc.; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2742":"<p><b>Title</b> Cefpodoxime / Histamine H2 Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of cefpodoxime if an H<sub>2</sub>-antagonist is initiated/dose increased. Separating the doses of the two agents by at least 2 hours might minimize the effects.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine*, Lafutidine, Nizatidine, RaNITIdine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Studies demonstrate the ability of H<sub>2</sub>-antagonists to reduce the bioavailability of cefpodoxime by as much as 40%.<sup>1,2</sup> The effects were minimized by administering the H<sub>2</sub>-antagonist at least 2 hours before cefpodoxime.<sup>1</sup> The increased gastric pH caused by the H<sub>2</sub>-antagonist may reduce cefpodoxime dissolution and subsequent absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Saathoff N, Lode H, Neider K, et al, “Pharmacokinetics of Cefpodoxime Proxetil and Interactions With an Antacid and an H<sub>2</sub>-Receptor Antagonist,” <i>Antimicrob Agents Chemother</i>, 1992, 36(4):796-800. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1354432\">[PubMed 1354432]</a></p>\n<p>2. Hughes GS, Heald DL, Barker KB, et al, “The Effects of Gastric pH and Food on the Pharmacokinetics of a New Oral Cephalosporin, Cefpodoxime Proxetil,” <i>Clin Pharmacol Ther</i>, 1989, 46(6):674-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2557183\">[PubMed 2557183]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2743":"<p><b>Title</b> Cefuroxime / Histamine H2 Receptor Antagonists</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to orally administered cefuroxime axetil. This interaction does not apply when cefuroxime is administered via the intravenous or intramuscular routes.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of oral cefuroxime axetil and H2 receptor antagonists.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 6 healthy volunteers, the AUC of cefuroxime (given as a single dose of 1,000 mg cefuroxime axetil) was reduced by more than 60% when coadministered with a combination of ranitidine and sodium bicarbonate.<sup>1</sup><br><br>In contrast, in a pharmacokinetic study of 7 dialysis patients, aluminum hydroxide (1,000 mg single dose) administered prior to cefuroxime axetil (1,000 mg single dose) had no effect on the maximum serum concentration or AUC of cefuroxime.<sup>2</sup><br><br>The cefuroxime axetil prescribing information states that because drugs that reduce gastric acidity may reduce the bioavailability of cefuroxime, the concomitant use of cefuroxime axetil and H2 receptor antagonists should be avoided.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sommers DK, van Wyk M, Moncrieff J, Schoeman HS. Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil. <i>Br J Clin Pharmacol</i>. 1984;18(4):535-539. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6091711\">[PubMed 6091711]</a></p>\n<p>2. Brink HS, Huisman RM, Geerlings W, de Jong PE. Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment. <i>Adv Perit Dial</i>. 1994;10:179-182. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7999822\">[PubMed 7999822]</a></p>\n<p>3. Ceftin (cefuroxime axetil) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2744":"<p><b>Title</b> Vitamin K Antagonists / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cimetidine may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> If possible, use an alternative H<sub>2</sub>-antagonist with concurrent coumarin derivative administration. If cimetidine must be used, monitor for increased therapeutic effects of the coumarin derivative when cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Cimetidine has been demonstrated in a number of reports to increase the hypoprothrombinemic effect of warfarin in warfarin-stable patients, at times resulting in bleeding.<sup>1,2,3,4,5</sup> The effect appears to be dose-related (with higher doses of cimetidine producing greater effects), and mediated by a cimetidine-induced inhibition of warfarin metabolism in the liver (hydroxylation). Other oral anticoagulants which undergo hydroxylation (eg, acenocoumarol, and phenindione) appear likewise effected in some,<sup>2</sup> but not all,<sup>6</sup> reports, whereas phenprocoumon (metabolized via glucuronidation) is not affected by cimetidine.<sup>2,7,8</sup> Other H<sub>2</sub>-antagonists do not appear to affect warfarin concentrations or effects, though isolated cases of bleeding have been reported.<sup>9,10,11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Flind AC, “Cimetidine and Oral Anticoagulants,” <i>Br Med J</i>, 1978, 2(6148):1367. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=719395\">[PubMed 719395]</a></p>\n<p>2. Serlin MJ, Sibeon RG, Mossman S, et al, “Cimetidine: Interaction With Oral Anticoagulants in Man,” <i>Lancet</i>, 1979, 2(8138):317-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=89387\">[PubMed 89387]</a></p>\n<p>3. Kerley B and Ali M, “Cimetidine Potentiation of Warfarin Action,” <i>Can Med Assoc J</i>, 1982, 126(2):116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7059881\">[PubMed 7059881]</a></p>\n<p>4. Silver BA and Bell WR, “Cimetidine Potentiation of the Hypoprothrombinemic Effect of Warfarin,” <i>Ann Intern Med</i>, 1979, 90(3):348-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=426403\">[PubMed 426403]</a></p>\n<p>5. Hetzel D, Birkett D, and Miners J, “Cimetidine Interaction With Warfarin,” <i>Lancet</i>, 1979, 2(8143):639. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=90304\">[PubMed 90304]</a></p>\n<p>6. Thijssen HH, Janssen GM, and Baars LG, “Lack of Effect of Cimetidine on Pharmacodynamics and Kinetics of Single Oral Doses of R- and S-acenocoumarol,” <i>Eur J Clin Pharmacol</i>, 1986, 30(5):619-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3758150\">[PubMed 3758150]</a></p>\n<p>7. van Rooij J, van der Meer FJ, Schoemaker HC, et al, “Comparison of the Effect of Grapefruit Juice and Cimetidine on Pharmacokinetics and Anticoagulant Effect of a Single Dose of Acenocoumarol,” <i>Br J Clin Pharmacol</i>, 1993, 35:548P.</p>\n<p>8. Harenberg J, Staiger CH, de Vries JX, et al, “Cimetidine Does Not Increase the Anticoagulant Effect of Phenprocoumon,” <i>Br J Clin Pharmacol</i>, 1982, 14(2):292-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7104184\">[PubMed 7104184]</a></p>\n<p>9. Serlin MJ, Sibeon RG, and Breckenridge AM, “Lack of Effect of Ranitidine on Warfarin Action,” <i>Br J Clin Pharmacol</i>, 1981, 12(6):791-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6122462\">[PubMed 6122462]</a></p>\n<p>10. O’Reilly RA, “Comparative Interaction of Cimetidine and Ranitidine With Racemic Warfarin in Man,” <i>Arch Intern Med</i>, 1984, 144(5):989-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6324710\">[PubMed 6324710]</a></p>\n<p>11. “Unrecognized Drug Interactions With Famotidine and Nizatidine,” <i>Arch Intern Med</i>, 1991, 151(4):810, 814, 815. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1672811\">[PubMed 1672811]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2745":"<p><b>Title</b> Alendronate / Aspirin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aspirin may enhance the adverse/toxic effect of Alendronate. Specifically, the incidence of upper gastrointestinal adverse events may be increased <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased upper gastrointestinal adverse events (eg, abdominal pain, nausea, vomiting, heartburn, dyspepsia, dysphagia, gastritis, esophagitis, perforation, ulcer, hemorrhage) if these agents are used concomitantly.</p> \n<p><b>Discussion</b> According to the alendronate prescribing information, in clinical studies, the incidence of upper gastrointestinal (GI) adverse events was increased in patients receiving concomitant therapy with alendronate and aspirin-containing compounds.<sup>1</sup><br><br>In contrast, in a clinical trial designed to assess the GI tolerability of a 70 mg once-weekly alendronate dosing regimen compared with placebo, a post-hoc analysis (N = 222) found no difference in the incidence of upper GI adverse events (eg, abdominal pain, nausea, vomiting, heartburn, dyspepsia, dysphagia, gastritis, esophagitis, perforation, ulcer, hemorrhage) between the alendronate and placebo groups among nonsteroidal anti-inflammatory drug (NSAID) users (9.3% vs 10.8%; <i>P</i> = 0.744).<sup>2</sup> While all NSAIDs were included in this analysis, aspirin was the most commonly used NSAID among patients in this trial.<sup>2</sup> An observational, retrospective analysis of alendronate users in the National Health Insurance program database in Taiwan found that aspirin use was not an independent risk factor for upper or lower GI bleeding.<sup>3</sup> Other NSAID use was found to be a risk factor for upper GI bleeding (hazard ratio [HR], 1.62; 95% confidence interval [CI], 1.00 to 2.56) and clopidogrel use was identified as a risk factor for upper (HR, 2.83; 95% CI, 1.01 to 7.9) and lower (HR, 5.07; 95% CI, 2.22 to 11.56) GI bleeding.<sup>3</sup> The incidence of other GI adverse effects was not assessed in this study.<sup>3</sup><br><br>The mechanism of this potential interaction is that both aspirin and alendronate have been associated with GI mucosal irritation and injury.<sup>1,4</sup> Their concomitant use may result in additive adverse GI effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fosamax (alendronate) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; February 2015.</p>\n<p>2. Cryer B, Miller P, Petruschke RA, Chen E, Geba GP, Papp AE. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. <i>Aliment Pharmacol Ther</i>. 2005;21(5):599-607. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15740544\">[PubMed 15740544]</a></p>\n<p>3. Peng YL, Hu HY, Luo JC, Hou MC, Lin HC, Lee FY. Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study. <i>Osteoporos Int</i>. 2014;25(5):1617-1623. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24566586\">[PubMed 24566586]</a></p>\n<p>4. Aggrenox (aspirin/dipyridamole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; September 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2748":"<p><b>Title</b> Alfentanil / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Alfentanil. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for intensified and/or prolonged effects of alfentanil in patients already receiving cimetidine. Alfentanil dose requirements may be reduced.</p> \n<p><b>Discussion</b> Cimetidine appears to reduce the hepatic metabolism of alfentanil, thus increasing alfentanil's half-life by 60% to 75%.<sup>1</sup> The study employed cimetidine in a dosage of 1200 mg/day for 2 days, followed by single dose of alfentanil (125 mcg/kg). Similarly, alfentanil prescribing information cautions that cimetidine can reduce the clearance of alfentanil, resulting in a reduced dose requirement and/or prolonged duration of alfentanil action.<sup>2</sup><br><br>The apparent mechanism of this interaction is inhibition of alfentanil metabolism by cimetidine, which is a well-known inhibitor of several cytochrome P450 enzymes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kienlen J, Levron JC, Aubas S, et al, “Pharmacokinetics of Alfentanil in Patients Treated With Either Cimetidine or Ranitidine,” <i>Drug Invest</i>, 1993, 6:257-62.</p>\n<p>2. Prescribing information. Alfenta (alfentanil). Decatur, IL: Taylor Pharmaceuticals, 06/05.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2749":"<p><b>Title</b> Alfentanil / DilTIAZem</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> DilTIAZem may increase the serum concentration of Alfentanil. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> For patients who are actively receiving or have recently received diltiazem, caution should be used in administering alfentanil. Monitor for increased anesthetic and respiratory depressant effects. Consider using lower doses of alfentanil, or using an alternative anesthetic.</p> \n<p><b>Discussion</b> Diltiazem has been reported to increase the AUC of alfentanil by 24%.<sup>1</sup> The time to extubation in this study was increased by 2.5 hours. No statistically-significant effect on time to awakening was noted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ahonen J, Olkkola KT, Salmenpera M, et al, “Effect of Diltiazem on Midazolam and Alfentanil Disposition in Patients Undergoing Coronary Artery Bypass Grafting,” <i>Anesthesiology</i>, 1996, 85(6):1246-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8968170\">[PubMed 8968170]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2750":"<p><b>Title</b> Propofol / Alfentanil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alfentanil may enhance the adverse/toxic effect of Propofol. Specifically the development of opisthotonus (severe hyperextension and spasticity resulting in arching or bridging position) and/or tonic clonic seizures. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased toxic effects of propofol if coadministered with alfentanil.</p> \n<p><b>Discussion</b> Coadministration of propofol and alfentanil has resulted in opisthotonus (severe hyperextension and spasticity resulting in arching or bridging position) and tonic clonic seizures in patients without history of epilepsy.<sup>1,2</sup> In the presence of alfentanil, reduced doses of propofol have been needed to achieve loss of consciousness and suppress the eyelash reflex. A greater hypotensive and heart rate response to propofol has also been noted.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Laycock GJ, “Opisthotonus and Propofol: A Possible Association,” <i>Anaesthesia</i>, 1988, 43(3):257. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3259082\">[PubMed 3259082]</a></p>\n<p>2. Wittenstein U and Lyle DJ, “Fits After Alfentanil and Propofol,” <i>Anaesthesia</i>, 1989, 44(6):532-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2502929\">[PubMed 2502929]</a></p>\n<p>3. Vuyk J, Engbers FH, Burm AG, et al, “Pharmacodynamic Interaction Between Propofol and Alfentanil when Given for Induction of Anesthesia,” <i>Anesthesiology</i>, 1996, 84(2):288-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8602658\">[PubMed 8602658]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2751":"<p><b>Title</b> Allopurinol / Angiotensin-Converting Enzyme Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Angiotensin-Converting Enzyme Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. <b>Severity</b> Major <b>Onset</b> Immediate (Sequence Important) <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> If allopurinol must be used in an angiotensin-converting enzyme inhibitor patient, monitor for evidence of hypersensitivity reactions following the initiation of allopurinol therapy for at least 5 weeks.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril*, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case reports suggest that the risk of allopurinol-related hypersensitivity reactions might be enhanced by concomitant angiotensin-converting enzyme inhibitor (ACEI) therapy.<sup>1,2</sup> Patients on chronic captopril therapy have experienced Stevens-Johnson syndrome (fatal), fever, arthralgia, and myalgia within 10 to 35 days after beginning allopurinol therapy. Another case report described anaphylaxis and myocardial infarction which developed 20 minutes after a single dose of allopurinol in a patient receiving enalapril.<sup>3</sup> Allopurinol can cause these effects in the absence of ACEI therapy.<sup>4</sup> This is particularly true in the presence of diuretics and renal dysfunction, both of which were present in some of these case report patients. However, in one case the patient improved when the captopril was discontinued.<sup>2</sup> The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pennell DJ, Nunan TO, O’Doherty MJ, et al, “Fatal Stevens-Johnson Syndrome in a Patient on Captopril and Allopurinol,” <i>Lancet</i>, 1984, 1(8374):463. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6142201\">[PubMed 6142201]</a></p>\n<p>2. Samanta A and Burden AC, “Fever, Myalgia, and Arthralgia in a Patient on Captopril and Allopurinol,” <i>Lancet</i>, 1984, 1(8378):679. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6142365\">[PubMed 6142365]</a></p>\n<p>3. Ahmad S, “Allopurinol and Enalapril. Drug-Induced Anaphylactic Coronary Spasm and Acute Myocardial Infarction,” <i>Chest</i>, 1995, 108(2):586. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7634908\">[PubMed 7634908]</a></p>\n<p>4. Burkle WS, “Allopurinol Hypersensitivity,” <i>Drug Intel Clin Pharm</i>, 1979, 13:218.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2752":"<p><b>Title</b> Allopurinol / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the absorption of Allopurinol. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Administer antacids at least 3 hours before allopurinol administration to reduce the potential risks of this interaction.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate<br><b>Exception</b> Sodium Bicarbonate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A single report describes three hemodialysis patients who failed to respond to allopurinol therapy when such was coadministered with aluminum hydroxide.<sup>1</sup> Patient response to allopurinol was successful when administered at least 3 hours before the antacid. Signs of therapy failure recurred in one patient when simultaneous administration of the two agents was reinitiated. No information is presently available about the effect of other antacids.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Weissman I and Krivoy N, “Interaction of Aluminum Hydroxide and Allopurinol in Patients on Chronic Hemodialysis,” <i>Ann Intern Med</i>, 1987, 107(5):787. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3662305\">[PubMed 3662305]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2753":"<p><b>Title</b> Ampicillin / Allopurinol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Allopurinol may enhance the potential for allergic or hypersensitivity reactions to Ampicillin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased incidence of skin rash (hypersensitivity reactions) during concomitant use of these agents.</p> \n<p><b>Discussion</b> Epidemiological data revealed an increased incidence of skin rash in patients taking ampicillin plus allopurinol (22%) versus those taking ampicillin alone (7.5%).<sup>1</sup> Another report showed similar results for both ampicillin and amoxicillin.<sup>2</sup> Whether this data demonstrates allopurinol potentiation of ampicillin/amoxicillin effects, or simply reflects allopurinol-independent effects, is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p> 1. Boston Collaborative Drug Surveillance Program. Excess of ampicillin rashes associated with allopurinol or hyperuricemia. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. <i>N Engl J Med</i>. 1972;286(10):505-507. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4258181\">[PubMed 4258181]</a></p>\n<p>2. Jick H, Porter JB. Potentiation of ampicillin skin reactions by allopurinol or hyperuricemia. <i>J Clin Pharmacol</i>. 1981;21(10):456-458. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6458626\">[PubMed 6458626]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2754":"<p><b>Title</b> Vitamin K Antagonists / Allopurinol</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Allopurinol may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased prothrombin times (PT)/therapeutic effects of oral anticoagulants if allopurinol is initiated/dose increased, or decreased effects if allopurinol is discontinued/dose decreased. Reductions in coumarin dosage will likely be needed.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Clinical reports describe increases in the hypoprothrombinemic response to oral anticoagulants (including warfarin and dicumarol) following the addition of allopurinol.<sup>1,2,3,4</sup> The incidence of adverse outcomes appears low ,<sup>5,6</sup> but at times the outcome can be quite significant. Noted changes in prothrombin time/clinical response has been reported to occur in as few as 2 days.<sup>3</sup> The mechanism of this interaction is not clear, but might be related to allopurinol's ability to inhibit the hepatic metabolism of oral anticoagulants.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. McInnes, GT, Lawson DH, and Jick H, “Acute Adverse Reactions Attributed to Allopurinol in Hospitalized Patients,” <i>Ann Rheum Dis</i>, 1981, 40(3):245-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7247470\">[PubMed 7247470]</a></p>\n<p>2. Self TH, Evans WE, and Ferguson T, “Drug Enhancement of Warfarin Activity,” <i>Lancet</i>, 1975, 2(7934):557-8 (letter). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=51384\">[PubMed 51384]</a></p>\n<p>3. Barry M and Feely J, “Allopurinol Influences Aminophenazone Elimination,” <i>Clin Pharmacokinet</i>, 1990, 19(2):167-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2379382\">[PubMed 2379382]</a></p>\n<p>4. Vesell ES, Passananti GT, and Greene FE, “Impairment of Drug Metabolism in Man by Allopurinol and Nortriptyline,” <i>N Engl J Med</i>, 1970, 283(27):1484-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4098480\">[PubMed 4098480]</a></p>\n<p>5. Pond SM, Graham GG, Wade DN, et al, “The Effects of Allopurinol and Clofibrate on the Elimination of Coumarin Anticoagulants in Man,” <i>Aus NZ J Med</i>, 1975, 5(4):324-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=52353\">[PubMed 52353]</a></p>\n<p>6. Rawlins MD and Smith SE, “Influence of Allopurinol on Drug Metabolism in Man,” <i>Br J Pharmacol</i>, 1973, 48(4):693-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4788211\">[PubMed 4788211]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2756":"<p><b>Title</b> Amoxicillin / Allopurinol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Allopurinol may enhance the potential for allergic or hypersensitivity reactions to Amoxicillin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased incidence of skin rash (hypersensitivity reactions) during concomitant use of these agents.</p> \n<p><b>Discussion</b> Epidemiological data revealed an increased incidence of skin rash in patients taking ampicillin plus allopurinol (22%) versus those taking ampicillin alone (7.5%).<sup>1</sup> Another report showed similar results for both ampicillin and amoxicillin.<sup>2</sup> Whether this data demonstrates allopurinol potentiation of ampicillin/amoxicillin effects, or simply reflects allopurinol-independent effects, is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Boston Collaborative Drug Surveillance Program, “Excess of Ampicillin Rashes Associated With Allopurinol or Hyperuricaemia,” <i>N Engl J Med</i>, 1972, 286(10):505-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4258181\">[PubMed 4258181]</a></p>\n<p>2. Jick H and Porter JB, “Potentiation of Ampicillin Skin Reactions by Allopurinol or Hyperuricemia,” <i>J Clin Pharmacol</i>, 1981, 21(10):456-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6458626\">[PubMed 6458626]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2757":"<p><b>Title</b> AzaTHIOprine / Allopurinol</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Allopurinol may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. More specifically, allopurinol may increase mercaptopurine serum concentrations and promote formation of active thioguanine nucleotides. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Reduce the azathioprine dose to one third to one quarter of the usual dose if used concomitantly with allopurinol, and monitor closely for systemic toxicity (particularly hematologic toxicity, nausea, and vomiting).</p> \n<p><b>Discussion</b> Several published case reports describe elevated systemic concentrations and toxic effects (particularly hematologic toxicity, nausea, and vomiting) when mercaptopurine (MP) or its prodrug azathioprine (AZA) is used in combination with allopurinol.<sup>1,2,3,4,5,6,7,8,9,10</sup> <br><br>MP metabolism occurs via 3 primary pathways: oxidation to inactive thiouric acid catalyzed by xanthine oxidase (XO); methylation to inactive methyl-mercaptopurine catalyzed by thiopurine S-methyl transferase (TPMT); and activation to thioguanine nucleotides in a process initiated by hypoxanthine-guanine phosphoribosyl transferase.<sup>11,12,13</sup> Inhibition of XO by allopurinol may increase systemic MP exposure and toxicity, particularly via inhibition of its presystemic metabolism.<sup>14,15,16,17,18,19</sup> US prescribing information for most MP and AZA products recommends a dose reduction of two-thirds to three-quarters when used with allopurinol in order to reduce this risk of toxicity.<sup>12,13</sup> <br><br>In patients who have a poor response to MP/AZA associated with a high ratio of methylmercaptopurine metabolites relative to thioguanine nucleotides, numerous case reports and clinical studies have described a potential favorable balance of efficacy and toxicity when combining reduced-dose MP/AZA with allopurinol.<sup>20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41</sup> Treatment with allopurinol may not only decrease XO mediated MP inactivation, it may also indirectly decrease TPMP mediated MP inactivation by promoting formation of an MP metabolite (thioxanthine) that inhibits TMPT.<sup>42</sup> In addition to enhancing therapeutic response in inflammatory bowel disease in some patients (preliminary results also suggest some potential use in other conditions, including autoimmune hepatitis), allopurinol may decrease MP/AZA hepatotoxicity<sup>38,39,40,41,42,43,44</sup> and enhance MP/AZA immunosuppression.<sup>21,26</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zazgornik J, Kopsa H, Schmidt P, Pils P, Kuschan K, Deutsch E. Increased danger of bone marrow damage in simultaneous azathioprine-allopurinol therapy. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1981;19(3):96-97. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7228457\">[PubMed 7228457]</a></p>\n<p>2. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. <i>Ann Pharmacother</i>. 1996;30(9):951-954. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8876853\">[PubMed 8876853]</a></p>\n<p>3. Berns A, Rubenfeld S, Rymzo WT Jr, Calabro JJ. Hazard of combining allopurinol and thiopurine. <i>N Engl J Med</i>. 1972;286(13):730-731. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5061067\">[PubMed 5061067]</a></p>\n<p>4. Cummins D, Sekar M, Halil O, Banner N. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. <i>Transplantation</i>. 1996;61(11):1661-1662. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8669118\">[PubMed 8669118]</a>]</p>\n<p>5. Weissman AM, Christian DG, Cornelis WA, Fortner CL. Allopurinol-mercaptopurine interaction. <i>J Am Pharm Assoc</i>. 1973 Jan;13(1):2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4682571\">[PubMed 4682571]</a></p>\n<p>6. Lennard L, Brown CB, Fox M, Maddocks JL. Azathioprine metabolism in kidney transplant recipients. <i>Br J Clin Pharmacol</i>. 1984;18(5):693-700. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6391532\">[PubMed 6391532]</a></p>\n<p>7. Kissel JT, Levy RJ, Mendell JR, Griggs RC. Azathioprine toxicity in neuromuscular disease. <i>Neurology</i>. 1986;36(1):35-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3941781\">[PubMed 3941781]</a></p>\n<p>8. Jeurissen ME, Boerbooms AM, van de Putte LB. Pancytopenia related to azathioprine in rheumatoid arthritis. <i>Ann Rheum Dis</i>. 1988;47(6):503-505. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3382271\">[PubMed 3382271]</a></p>\n<p>9. Venkat Raman G, Sharman VL, Lee HA. Azathioprine and allopurinol: a potentially dangerous combination. <i>J Intern Med</i>. 1990;228(1):69-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2384739\">[PubMed 2384739]</a></p>\n<p>10. Gregoriano C, Ceschi A, Rauber-Luthy C, et al. Acute thiopurine overdose: analysis of reports to a National Poison Centre 1995-2013. <i>PLoS One</i>. 2014;9(1):e86390. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24489721\">[PubMed 24489721]</a> </p>\n<p>11. <i>Purixan</i> (mercaptopurine) [prescribing information]. Franklin, TN: Rare Disease Therapeutics, Inc; April 2014.</p>\n<p>12. <i>Purinethiol</i> (mercaptopurine) [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; April 2011.</p>\n<p>13. <i>Imuran</i> (azathioprine) [prescribing information]. San Diego, CA: Prometheus Laboratories Inc; February 2014.</p>\n<p>14. Zimm S, Collins JM, O'Neill D, Chabner BA, Poplack DG. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. <i>Clin Pharmacol Ther</i>. 1983;34(6):810-817. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6580097\">[PubMed 6580097]</a></p>\n<p>15. Coffey JJ, White CA, Lesk AB, Rogers WI, Serpick AA. Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine (NSC 755) in cancer patients. <i>Cancer Res</i>. 1972;32(6):1283-1289. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5030828\">[PubMed 5030828]</a></p>\n<p>16. Brooks RJ, Dorr RT, Durie BG. Interaction of allopurinol with 6-mercaptopurine and azathioprine. <i>Biomed Pharmacother</i>. 1982;36(4):217-222. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6891901\">[PubMed 6891901]</a></p>\n<p>17. Zimm S, Ettinger LJ, Holcenberg JS, et al. Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. <i>Cancer Res</i>. 1985;45(4):1869-1873. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4038917\">[PubMed 4038917]</a></p>\n<p>18. Keuzenkamp-Jansen CW, DeAbreu RA, Bokkerink JP, Lambooy MA, Trijbels JM. Metabolism of intravenously administered high-dose 6-mercaptopurine with and without allopurinol treatment in patients with non-Hodgkin lymphoma. <i>J Pediatr Hematol Oncol</i>. 1996;18(2):145-150. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8846126\">[PubMed 8846126]</a></p>\n<p>19. Seinen ML, van Asseldonk DP, de Boer NK, et al. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study. <i>J Crohns Colitis</i>. 2013;7(10):812-819. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23317929\">[PubMed 23317929]</a></p>\n<p>20. Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. <i>Aliment Pharmacol Ther</i>. 2005;22(5):441-446. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16128682\">[PubMed 16128682]</a></p>\n<p>21. Chocair P, Duley J, Simmonds HA, et al. Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. <i>Lancet</i>. 1993;342(8863):83-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8100914\">[PubMed 8100914]</a></p>\n<p>22. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB.Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. <i>Clin Gastroenterol Hepatol</i>. 2007;5(2):209-214. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296529\">[PubMed 17296529]</a></p>\n<p>23. Rahhal RM, Bishop WP. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. <i>Inflamm Bowel Dis</i>. 2008;14(12):1678-1682. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18521913\">[PubMed 18521913]</a></p>\n<p>24. Leung Y, Sparrow MP, Schwartz M, Hanauer SB. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. <i>J Crohns Colitis</i>. 2009;3(3):162-167. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21172265\">[PubMed 21172265]</a></p>\n<p>25. Dunkin D, Kerkar N, Arnon R, Suchy F, Miloh T. Allopurinol salvage therapy in pediatric overlap autoimmune hepatitis-primary sclerosing cholangitis with 6-MMP toxicity. <i>J Pediatr Gastroenterol Nutr</i>. 2010;51(4):524-526. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20531025\">[PubMed 20531025]</a></p>\n<p>26. Govani SM, Higgins PD. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. <i>J Crohns Colitis</i>. 2010;4(4):444-449. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21122542\">[PubMed 21122542]</a></p>\n<p>27. Gerich ME, Quiros JA, Marcin JP, Tennyson L, Henthorn M, Prindiville TP. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine. <i>J Crohns Colitis</i>. 2010;4(5):546-552. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21122558\">[PubMed 21122558]</a></p>\n<p>28. Gardiner SJ, Gearry RB, Burt MJ, et al. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. <i>J Gastroenterol Hepatol</i>. 2011;26(1):49-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21175793\">[PubMed 21175793]</a></p>\n<p>29. Seinen ML, de Boer NK, Smid K, et al. Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during low-dose thiopurine therapy: preliminary data of an ongoing series. <i>Nucleosides Nucleotides Nucleic Acids</i>. 2011;30(12):1085-1090. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22132961\">[PubMed 22132961]</a></p>\n<p>30. Seinen ML, de Boer NK, van Hoorn ME, van Bodegraven AA, Bouma G. Safe use of allopurinol and low-dose mercaptopurine therapy during pregnancy in an ulcerative colitis patient. <i>Inflamm Bowel Dis</i>. 2013;19(3):E37. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22407929\">[PubMed 22407929]</a></p>\n<p>31. Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. <i>Inflamm Bowel Dis</i>. 2013;19(2):363-369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22605661\">[PubMed 22605661]</a></p>\n<p>32. Appell ML, Wagner A, Hindorf U. A skewed thiopurine metabolism is a common clinical phenomenon that can be successfully managed with a combination of low-dose azathioprine and allopurinol. <i>J Crohns Colitis</i>. 2013;7(6):510-513. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23168376\">[PubMed 23168376]</a></p>\n<p>33. Al-Shamma S, Eross B, Mclaughlin S. Use of a xanthine oxidase inhibitor in autoimmune hepatitis. <i>Hepatology</i>. 2013;57(3):1281-1282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23238820\">[PubMed 23238820]</a></p>\n<p>34. de Boer YS, van Gerven NM, de Boer NK, Mulder CJ, Bouma G, van Nieuwkerk CM. Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis. <i>Aliment Pharmacol Ther</i>. 2013;37(6):640-646. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23347359\">[PubMed 23347359]</a></p>\n<p>35. Curkovic I, Rentsch KM, Frei P, et al. Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations. <i>Eur J Clin Pharmacol</i>. 2013;69(8):1521-1531. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23588559\">[PubMed 23588559]</a></p>\n<p>36. Brackett J, Schafer ES, Leung DH, Bernhardt MB. Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism. <i>Pediatr Blood Cancer</i>. 2014;61(6):1114-1117. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24376133\">[PubMed 24376133]</a></p>\n<p>37. Ihekweazu FD, Kellermayer R. Allopurinol: a useful adjunct to thiopurine therapy for pediatric ulcerative colitis in the biologic era [published online February 28, 2014]. <i>J Pediatr Gastroenterol Nutr</i>. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24590210\">[PubMed 24590210]</a></p>\n<p>38. Smith MA, Blaker P, Marinaki AM, Anderson SH, Irving PM, Sanderson JD. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. <i>J Crohns Colitis</i>. 2012;6(9):905-912. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22386736\">[PubMed 22386736]</a></p>\n<p>39. Hoentjen F, Hanauer SB, de Boer NK, Rubin DT. Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction. <i>Dig Dis Sci</i>. 2012;57(1):250-253. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22147254\">[PubMed 22147254]</a></p>\n<p>40. Ansari A, Elliott T, Baburajan B, et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. <i>Aliment Pharmacol Ther</i>. 2008;28(6):734-741. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19145729\">[PubMed 19145729]</a></p>\n<p>41. Ansari A, Patel N, Sanderson J, O'Donohue J, Duley JA, Florin TH. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. <i>Aliment Pharmacol Ther</i>. 2010;31(6):640-647. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20015102\">[PubMed 20015102]</a></p>\n<p>42. Blaker PA, Arenas-Hernandez M, Smith MA, et al. Mechanism of allopurinol induced TPMT inhibition. <i>Biochem Pharmacol</i>. 2013;86(4):539-547. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23770457\">[PubMed 23770457]</a></p>\n<p>43. Lee AU, Farrell GC. Mechanism of azathioprine-induced injury to hepatocytes: roles of glutathione depletion and mitochondrial injury. <i>J Hepatol</i>. 2001;35(6):756-764. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11738103\">[PubMed 11738103]</a></p>\n<p>44. Tapner MJ, Jones BE, Wu WM, Farrell GC. Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. <i>J Hepatol</i>. 2004;40(3):454-463. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15123360\">[PubMed 15123360]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2758":"<p><b>Title</b> Mercaptopurine / Allopurinol</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Allopurinol may increase the serum concentration of Mercaptopurine. Allopurinol may also promote formation of active thioguanine nucleotides. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Reduce the mercaptopurine dose to one third to one quarter of the usual dose if used concomitantly with allopurinol, and monitor closely for systemic toxicity (particularly hematologic toxicity, nausea, and vomiting). US prescribing information for mercaptopurine oral suspension (Purixan brand) states that it should not be used with allopurinol.</p> \n<p><b>Discussion</b> Several published case reports describe elevated systemic concentrations and toxic effects (particularly hematologic toxicity, nausea, and vomiting) when mercaptopurine (MP) or its prodrug azathioprine (AZA) is used in combination with allopurinol.<sup>1,2,3,4,5,6,7,8,9,10</sup> <br><br>MP metabolism occurs via 3 primary pathways: oxidation to inactive thiouric acid catalyzed by xanthine oxidase (XO); methylation to inactive methyl-mercaptopurine catalyzed by thiopurine S-methyl transferase (TPMT); and activation to thioguanine nucleotides in a process initiated by hypoxanthine-guanine phosphoribosyl transferase.<sup>11,12,13</sup> Inhibition of XO by allopurinol may increase systemic MP exposure and toxicity, particularly via inhibition of its presystemic metabolism.<sup>14,15,16,17,18,19</sup> US prescribing information for most MP and AZA products recommends a dose reduction of two-thirds to three-quarters when used with allopurinol in order to reduce this risk of toxicity.<sup>12,13</sup> <br><br>In patients who have a poor response to MP/AZA associated with a high ratio of methylmercaptopurine metabolites relative to thioguanine nucleotides, numerous case reports and clinical studies have described a potential favorable balance of efficacy and toxicity when combining reduced-dose MP/AZA with allopurinol.<sup>20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41</sup> Treatment with allopurinol may not only decrease XO mediated MP inactivation, it may also indirectly decrease TPMP mediated MP inactivation by promoting formation of an MP metabolite (thioxanthine) that inhibits TMPT.<sup>42</sup> In addition to enhancing therapeutic response in inflammatory bowel disease in some patients (preliminary results also suggest some potential use in other conditions, including autoimmune hepatitis), allopurinol may decrease MP/AZA hepatotoxicity<sup>38,39,40,41,42,43,44</sup> and enhance MP/AZA immunosuppression.<sup>21,26</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zazgornik J, Kopsa H, Schmidt P, Pils P, Kuschan K, Deutsch E. Increased danger of bone marrow damage in simultaneous azathioprine-allopurinol therapy. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1981;19(3):96-97. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7228457\">[PubMed 7228457]</a></p>\n<p>2. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. <i>Ann Pharmacother</i>. 1996;30(9):951-954. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8876853\">[PubMed 8876853]</a></p>\n<p>3. Berns A, Rubenfeld S, Rymzo WT Jr, Calabro JJ. Hazard of combining allopurinol and thiopurine. <i>N Engl J Med</i>. 1972;286(13):730-731. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5061067\">[PubMed 5061067]</a></p>\n<p>4. Cummins D, Sekar M, Halil O, Banner N. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. <i>Transplantation</i>. 1996;61(11):1661-1662. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8669118\">[PubMed 8669118]</a>]</p>\n<p>5. Weissman AM, Christian DG, Cornelis WA, Fortner CL. Allopurinol-mercaptopurine interaction. <i>J Am Pharm Assoc</i>. 1973 Jan;13(1):2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4682571\">[PubMed 4682571]</a></p>\n<p>6. Lennard L, Brown CB, Fox M, Maddocks JL. Azathioprine metabolism in kidney transplant recipients. <i>Br J Clin Pharmacol</i>. 1984;18(5):693-700. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6391532\">[PubMed 6391532]</a></p>\n<p>7. Kissel JT, Levy RJ, Mendell JR, Griggs RC. Azathioprine toxicity in neuromuscular disease. <i>Neurology</i>. 1986;36(1):35-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3941781\">[PubMed 3941781]</a></p>\n<p>8. Jeurissen ME, Boerbooms AM, van de Putte LB. Pancytopenia related to azathioprine in rheumatoid arthritis. <i>Ann Rheum Dis</i>. 1988;47(6):503-505. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3382271\">[PubMed 3382271]</a></p>\n<p>9. Venkat Raman G, Sharman VL, Lee HA. Azathioprine and allopurinol: a potentially dangerous combination. <i>J Intern Med</i>. 1990;228(1):69-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2384739\">[PubMed 2384739]</a></p>\n<p>10. Gregoriano C, Ceschi A, Rauber-Luthy C, et al. Acute thiopurine overdose: analysis of reports to a National Poison Centre 1995-2013. <i>PLoS One</i>. 2014;9(1):e86390. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24489721\">[PubMed 24489721]</a> </p>\n<p>11. <i>Purixan</i> (mercaptopurine) [prescribing information]. Franklin, TN: Rare Disease Therapeutics, Inc; April 2014.</p>\n<p>12. <i>Purinethiol</i> (mercaptopurine) [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; April 2011.</p>\n<p>13. <i>Imuran</i> (azathioprine) [prescribing information]. San Diego, CA: Prometheus Laboratories Inc; February 2014.</p>\n<p>14. Zimm S, Collins JM, O'Neill D, Chabner BA, Poplack DG. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. <i>Clin Pharmacol Ther</i>. 1983;34(6):810-817. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6580097\">[PubMed 6580097]</a></p>\n<p>15. Coffey JJ, White CA, Lesk AB, Rogers WI, Serpick AA. Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine (NSC 755) in cancer patients. <i>Cancer Res</i>. 1972;32(6):1283-1289. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5030828\">[PubMed 5030828]</a></p>\n<p>16. Brooks RJ, Dorr RT, Durie BG. Interaction of allopurinol with 6-mercaptopurine and azathioprine. <i>Biomed Pharmacother</i>. 1982;36(4):217-222. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6891901\">[PubMed 6891901]</a></p>\n<p>17. Zimm S, Ettinger LJ, Holcenberg JS, et al. Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. <i>Cancer Res</i>. 1985;45(4):1869-1873. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4038917\">[PubMed 4038917]</a></p>\n<p>18. Keuzenkamp-Jansen CW, DeAbreu RA, Bokkerink JP, Lambooy MA, Trijbels JM. Metabolism of intravenously administered high-dose 6-mercaptopurine with and without allopurinol treatment in patients with non-Hodgkin lymphoma. <i>J Pediatr Hematol Oncol</i>. 1996;18(2):145-150. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8846126\">[PubMed 8846126]</a></p>\n<p>19. Seinen ML, van Asseldonk DP, de Boer NK, et al. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study. <i>J Crohns Colitis</i>. 2013;7(10):812-819. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23317929\">[PubMed 23317929]</a></p>\n<p>20. Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. <i>Aliment Pharmacol Ther</i>. 2005;22(5):441-446. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16128682\">[PubMed 16128682]</a></p>\n<p>21. Chocair P, Duley J, Simmonds HA, et al. Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. <i>Lancet</i>. 1993;342(8863):83-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8100914\">[PubMed 8100914]</a></p>\n<p>22. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB.Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. <i>Clin Gastroenterol Hepatol</i>. 2007;5(2):209-214. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296529\">[PubMed 17296529]</a></p>\n<p>23. Rahhal RM, Bishop WP. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. <i>Inflamm Bowel Dis</i>. 2008;14(12):1678-1682. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18521913\">[PubMed 18521913]</a></p>\n<p>24. Leung Y, Sparrow MP, Schwartz M, Hanauer SB. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. <i>J Crohns Colitis</i>. 2009;3(3):162-167. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21172265\">[PubMed 21172265]</a></p>\n<p>25. Dunkin D, Kerkar N, Arnon R, Suchy F, Miloh T. Allopurinol salvage therapy in pediatric overlap autoimmune hepatitis-primary sclerosing cholangitis with 6-MMP toxicity. <i>J Pediatr Gastroenterol Nutr</i>. 2010;51(4):524-526. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20531025\">[PubMed 20531025]</a></p>\n<p>26. Govani SM, Higgins PD. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. <i>J Crohns Colitis</i>. 2010;4(4):444-449. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21122542\">[PubMed 21122542]</a></p>\n<p>27. Gerich ME, Quiros JA, Marcin JP, Tennyson L, Henthorn M, Prindiville TP. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine. <i>J Crohns Colitis</i>. 2010;4(5):546-552. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21122558\">[PubMed 21122558]</a></p>\n<p>28. Gardiner SJ, Gearry RB, Burt MJ, et al. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio. <i>J Gastroenterol Hepatol</i>. 2011;26(1):49-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21175793\">[PubMed 21175793]</a></p>\n<p>29. Seinen ML, de Boer NK, Smid K, et al. Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during low-dose thiopurine therapy: preliminary data of an ongoing series. <i>Nucleosides Nucleotides Nucleic Acids</i>. 2011;30(12):1085-1090. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22132961\">[PubMed 22132961]</a></p>\n<p>30. Seinen ML, de Boer NK, van Hoorn ME, van Bodegraven AA, Bouma G. Safe use of allopurinol and low-dose mercaptopurine therapy during pregnancy in an ulcerative colitis patient. <i>Inflamm Bowel Dis</i>. 2013;19(3):E37. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22407929\">[PubMed 22407929]</a></p>\n<p>31. Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. <i>Inflamm Bowel Dis</i>. 2013;19(2):363-369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22605661\">[PubMed 22605661]</a></p>\n<p>32. Appell ML, Wagner A, Hindorf U. A skewed thiopurine metabolism is a common clinical phenomenon that can be successfully managed with a combination of low-dose azathioprine and allopurinol. <i>J Crohns Colitis</i>. 2013;7(6):510-513. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23168376\">[PubMed 23168376]</a></p>\n<p>33. Al-Shamma S, Eross B, Mclaughlin S. Use of a xanthine oxidase inhibitor in autoimmune hepatitis. <i>Hepatology</i>. 2013;57(3):1281-1282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23238820\">[PubMed 23238820]</a></p>\n<p>34. de Boer YS, van Gerven NM, de Boer NK, Mulder CJ, Bouma G, van Nieuwkerk CM. Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis. <i>Aliment Pharmacol Ther</i>. 2013;37(6):640-646. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23347359\">[PubMed 23347359]</a></p>\n<p>35. Curkovic I, Rentsch KM, Frei P, et al. Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations. <i>Eur J Clin Pharmacol</i>. 2013;69(8):1521-1531. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23588559\">[PubMed 23588559]</a></p>\n<p>36. Brackett J, Schafer ES, Leung DH, Bernhardt MB. Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism. <i>Pediatr Blood Cancer</i>. 2014;61(6):1114-1117. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24376133\">[PubMed 24376133]</a></p>\n<p>37. Ihekweazu FD, Kellermayer R. Allopurinol: a useful adjunct to thiopurine therapy for pediatric ulcerative colitis in the biologic era [published online February 28, 2014]. <i>J Pediatr Gastroenterol Nutr</i>. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24590210\">[PubMed 24590210]</a></p>\n<p>38. Smith MA, Blaker P, Marinaki AM, Anderson SH, Irving PM, Sanderson JD. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. <i>J Crohns Colitis</i>. 2012;6(9):905-912. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22386736\">[PubMed 22386736]</a></p>\n<p>39. Hoentjen F, Hanauer SB, de Boer NK, Rubin DT. Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction. <i>Dig Dis Sci</i>. 2012;57(1):250-253. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22147254\">[PubMed 22147254]</a></p>\n<p>40. Ansari A, Elliott T, Baburajan B, et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. <i>Aliment Pharmacol Ther</i>. 2008;28(6):734-741. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19145729\">[PubMed 19145729]</a></p>\n<p>41. Ansari A, Patel N, Sanderson J, O'Donohue J, Duley JA, Florin TH. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. <i>Aliment Pharmacol Ther</i>. 2010;31(6):640-647. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20015102\">[PubMed 20015102]</a></p>\n<p>42. Blaker PA, Arenas-Hernandez M, Smith MA, et al. Mechanism of allopurinol induced TPMT inhibition. <i>Biochem Pharmacol</i>. 2013;86(4):539-547. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23770457\">[PubMed 23770457]</a></p>\n<p>43. Lee AU, Farrell GC. Mechanism of azathioprine-induced injury to hepatocytes: roles of glutathione depletion and mitochondrial injury. <i>J Hepatol</i>. 2001;35(6):756-764. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11738103\">[PubMed 11738103]</a></p>\n<p>44. Tapner MJ, Jones BE, Wu WM, Farrell GC. Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. <i>J Hepatol</i>. 2004;40(3):454-463. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15123360\">[PubMed 15123360]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2759":"<p><b>Title</b> CarBAMazepine / Allopurinol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Allopurinol may increase the serum concentration of CarBAMazepine. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor for increased carbamazepine concentrations and signs/symptoms of carbamazepine toxicity if allopurinol is initiated/dose is increased. A dosage reduction of carbamazepine may be needed.</p> \n<p><b>Discussion</b> A small study reported an increase in serum carbamazepine concentrations of at least 30% in 6 of 7 patients.<sup>1</sup> The full effect took several weeks to occur, and a carbamazepine dose reduction was needed in 3 patients. In contrast, a study in mice found that concurrent allopurinol (at doses of 5, 15, or 45 mg/kg for 5 days) did not alter the anticonvulsant activity or plasma concentrations of carbamazepine.<sup>2</sup><br><br>The mechanism of this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mikati M, Erba G, Skousteli H, et al, “Pharmacokinetic Study of Allopurinol in Resistant Epilepsy: Evidence of Significant Drug Interactions,” <i>Neurology</i>, 1990, 40 (Suppl 1):138.</p>\n<p>2. Parada-Turska J, Czuczwar M, Kis J, et al, “Allopurinol Does Not Affect the Anticonvulsant Activity of Carbamazepine and Valproate in Maximal Electroshock-Induced Convulsions in Mice,” <i>Pol J Pharmacol</i>, 2004, 56(1):67-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15047979\">[PubMed 15047979]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2760":"<p><b>Title</b> ChlorproPAMIDE / Allopurinol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Allopurinol may increase the serum concentration of ChlorproPAMIDE. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic/toxic effects of chlorpropamide if allopurinol is initiated/dose increased, or decreased effects if allopurinol is discontinued/dose decreased.</p> \n<p><b>Discussion</b> In one observational study, 6 patients with normal renal function received the combination of chlorpropamide (1 gram single dose) and allopurinol.<sup>1</sup> The chlorpropamide half-life was more than 4.6-fold greater in 1 patient, 1.5- to 1.2-fold greater in 2 patients, and no different in 3 patients, when compared with the chlorpropamide half-life in 14 healthy volunteers who received chlorpropamide alone.<sup>1</sup> <br><br>The mechanism of this interaction has not been fully investigated, but allopurinol may reduce chlorpropamide renal tubular excretion.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Petitpierre B, Perrin L, Rudhardt M, Herrera A, Fabre J. Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy. <i>Int J Clin Pharmacol</i>. 1972;6(2):120-124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4638970\">[PubMed 4638970]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2762":"<p><b>Title</b> Cyclophosphamide / Allopurinol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Allopurinol may enhance the adverse/toxic effect of Cyclophosphamide. Specifically, bone marrow suppression. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects (eg, changes in CBC) of cyclophosphamide if allopurinol is initiated or the dose is increased, especially in patients receiving long-term allopurinol therapy (eg, for gout).</p> \n<p><b>Discussion</b> Allopurinol has been reported to increase the bone marrow suppressant effects of cyclophosphamide as much as threefold.<sup>1</sup> A pharmacokinetic study in 11 individuals demonstrated an average increase in toxic cyclophosphamide metabolites of 37.5%.<sup>2</sup> Another study failed to confirm this interaction.<sup>3</sup> The mechanism is not known, but might be related to allopurinol's effects on liver metabolism or renal excretion of cyclophosphamide metabolites.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Boston Collaborative Drug Surveillance Program, “Allopurinol and Cytotoxic Drugs. Interaction in Relation to Bone Marrow Depression,” <i>JAMA</i>, 1974, 227(9):1036-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4405931\">[PubMed 4405931]</a></p>\n<p>2. Witten J, Frederiksen PL, and Mouridsen HT, “The Pharmacokinetics of Cyclophosphamide in Man After Treatment With Allopurinol,” <i>Acta Pharmacol Toxicol (Copenh)</i>, 1980, 46(5):392-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7376891\">[PubMed 7376891]</a></p>\n<p>3. Stolbach L, Begg C, Bennett JM, et al, “Evaluation of Bone Marrow Toxic Reaction in Patients Treated With Allopurinol,” <i>JAMA</i>, 1982, 247(3):334-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7033573\">[PubMed 7033573]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2763":"<p><b>Title</b> Theophylline Derivatives / Allopurinol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Allopurinol may increase the serum concentration of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of theophylline derivatives if allopurinol is initiated or the dose is increased.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A case report describes a patient on theophylline (450 mg/day) whose serum concentrations increased 38% approximately 2 days following the addition of allopurinol.<sup>1</sup> Pharmacokinetic evaluations of this potential interaction in healthy subjects demonstrated a 27% increase in theophylline AUC when given allopurinol 600 mg/day for 14 days.<sup>2</sup> Studies using 300 mg/day of allopurinol failed to show any notable effect on theophylline.<sup>3,4</sup> Inhibition of theophylline metabolism in the liver is a proposed mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Barry M and Feely J, “Allopurinol Influences Amiphenazone Elimination,” <i>Clin Pharmacokinet</i>, 1990, 19(2):167-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2379382\">[PubMed 2379382]</a></p>\n<p>2. Manfredi RL and Vesell ES, “Inhibition of Theophylline Metabolism by Long-Term Allopurinol Administration,” <i>Clin Pharmacol Ther</i>, 1981, 29(2):224-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7460486\">[PubMed 7460486]</a></p>\n<p>3. Vozeh S, Powell JR, Cupit GC, et al, “Influence of Allopurinol on Theophylline Disposition in Adults,” <i>Clin Pharmacol Ther</i>, 1980, 27(2):194-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7353339\">[PubMed 7353339]</a></p>\n<p>4. Grygiel JJ, Wing LM, Farkas J, et al, “Effects of Allopurinol on Theophylline Metabolism and Clearance,” <i>Clin Pharmacol Ther</i>, 1979, 26(5):660-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=498708\">[PubMed 498708]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2764":"<p><b>Title</b> Famciclovir / Allopurinol</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Allopurinol does not appear to affect serum concentration of Famciclovir. Famciclovir does not appear to affect serum concentration of Allopurinol. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 12 healthy volunteers, pharmacokinetic variables for famciclovir (500 mg single oral dose) were unchanged following 6 days of allopurinol (300 mg daily).<sup>1</sup> Allopurinol pharmacokinetic variables were unaffected by the single famciclovir dose.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fowles SE, Pratt SK, Laroche J, et al, “Lack of a Pharmacokinetic Interaction Between Oral Famciclovir and Allopurinol in Healthy Volunteers,” <i>Eur J Clin Pharmacol</i>, 1994, 46(4):355-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7957522\">[PubMed 7957522]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2766":"<p><b>Title</b> Levodopa / Benzodiazepines</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Benzodiazepines may diminish the therapeutic effect of Levodopa. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of levodopa if a benzodiazepines initiated/dose increased, or increased effects if a benzodiazepine is discontinued/dose decreased.</p>\n<div>\n <p><b>Benzodiazepines Interacting Members</b> ALPRAZolam, Bromazepam, ChlordiazePOXIDE*, CloBAZam, ClonazePAM, Clorazepate, DiazePAM*, Estazolam, Ethyl Loflazepate, Etizolam, Flunitrazepam, Flurazepam, Loprazolam, LORazepam, Lormetazepam, Midazolam, Nitrazepam, Nordazepam, Oxazepam, Prazepam, Quazepam, Temazepam, Tofisopam, Triazolam</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Reports describe a loss in the control of parkinsonism when patients stable on levodopa were administered various benzodiazepines.<sup>1,2</sup> Some data refute these observations.<sup>3</sup> The incidence and mechanism for the apparent interaction are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hunter KR, Stern GM, and Laurence DR, “Use of Levodopa With Other Drugs,” <i>Lancet</i>, 1970, 2(7686):1283-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4098781\">[PubMed 4098781]</a></p>\n<p>2. Yosselson-Superstine S and Lipman AG, “Chlordiazepoxide Interaction With Levodopa,” <i>Ann Intern Med</i>, 1982, 96(2):259-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7059086\">[PubMed 7059086]</a></p>\n<p>3. van de Vijver DA, Roos RA, Jansen PA, et al, “Influence of Benzodiazepines on Antiparkinsonian Drug Treatment in Levodopa Users,” <i>Acta Neurol Scand</i>, 2002, 105(1):8-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11903102\">[PubMed 11903102]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2767":"<p><b>Title</b> Benzodiazepines / Theophylline Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Theophylline Derivatives may diminish the therapeutic effect of Benzodiazepines. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of benzodiazepines if a theophylline derivative is initiated/dose increased, or increased effects if a theophylline derivative is discontinued/dose decreased. Theophylline therapy may complicate the use of benzodiazepines in ICU/conscious sedation.</p>\n<div>\n <p><b>Benzodiazepines Interacting Members</b> ALPRAZolam*, Bromazepam, ChlordiazePOXIDE, CloBAZam, ClonazePAM, Clorazepate, DiazePAM*, Estazolam, Ethyl Loflazepate, Etizolam, Flunitrazepam, Flurazepam, Loprazolam, LORazepam, Lormetazepam, Midazolam, Nitrazepam, Nordazepam, Oxazepam, Prazepam, Quazepam, Temazepam, Tofisopam, Triazolam</p>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline*, Dyphylline, Theophylline*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Theophylline is reported to reduce the anxiolytic effects of diazepam and alprazolam.<sup>1,2</sup> Aminophylline has been similarly implicated.<sup>3,4</sup> Proposed mechanisms include: a) xanthine blockade of adenosine receptors; or b) xanthine-induced metabolism of benzodiazepines.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Henauer SA, Hollister LE, Gillespie HK, et al, “Theophylline Antagonizes Diazepam-Induced Psychomotor Impairment,” <i>Eur J Clin Pharmacol</i>, 1983, 25(6):743-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6662173\">[PubMed 6662173]</a></p>\n<p>2. Tuncok Y, Akpinar O, Guven H, et al, “The Effects of Theophylline on Serum Alprazolam Levels,”<i> Int J Clin Pharmacol Ther</i>, 1994, 32(12):642-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7881701\">[PubMed 7881701]</a></p>\n<p>3. Niemand D, Martinell S, Arvidsson S, et al, “Aminophylline Inhibition of Diazepam Sedation: Is Adenosine Blockade of GABA-Receptors the Mechanism?” <i>Lancet</i>, 1984, 1(8374):463-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6142202\">[PubMed 6142202]</a></p>\n<p>4. Arvidsson SB, Ekstrom-Jodal B, Martinell SA, et al, “Aminophylline Antagonises Diazepam Sedation,” <i>Lancet</i>, 1982, 2(8313):1467. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6129542\">[PubMed 6129542]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2768":"<p><b>Title</b> LORazepam / Cholestyramine Resin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cholestyramine Resin may decrease the serum concentration of LORazepam. This has been reported when given in combination with neomycin. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> A single report describes decreased serum lorazepam concentrations when given concomitantly with both cholestyramine and neomycin, but not with either agent alone.<sup>1</sup> Lorazepam clearance was increased 34%. The mechanism is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Herman RJ, Van Pham JD, and Szakacs CB, “Disposition of Lorazepam in Human Beings: Enterohepatic Recirculation and First-Pass Effect,” <i>Clin Pharmacol Ther</i>, 1989, 46(1):18-25. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2743706\">[PubMed 2743706]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2770":"<p><b>Title</b> LORazepam / Loxapine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Loxapine may enhance the adverse/toxic effect of LORazepam. Specifically, prolonged stupor, respiratory depression, and/or hypotension. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased lethargy, stupor, respiratory depression, and/or hypotension if loxapine and lorazepam are combined.</p> \n<p><b>Discussion</b> Three case reports describe the rapid development of drug-related toxicity (stupor, respiratory depression, and hypotension) in patients receiving concomitant oral loxapine and lorazepam.<sup>1,2</sup> Recovery occurred within hours in all cases. In a study of 18 healthy volunteers, the combination of inhaled loxapine (10 mg single dose) and lorazepam (1 mg intramuscularly single dose) resulted in increased sedation (as measured by a visual analog scale) but had no effect on heart rate, blood pressure, or respiratory rate compared with either drug alone.<sup>3</sup> <br><br>The mechanism of this potential interaction is likely due to additive CNS depressant effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cohen S, Khan A. Respiratory distress with the use of lorazepam in mania. <i>J Clin Psychopharmacol</i>. 1987;7(3):199-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3597810\">[PubMed 3597810]</a></p>\n<p>2. Battaglia J, Thornton L, Young C. Loxapine-lorazepam-induced hypotension and stupor. <i>J Clin Psychopharmacol</i>. 1989;9(3):227-228. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2738184\">[PubMed 2738184]</a></p>\n<p>3. Spyker DA, Cassella JV, Stoltz RR, Yeung PP. Inhaled loxapine and intramuscular lorazepam in healthy volunteers: a randomized placebo-controlled drug-drug interaction study. <i>Pharmacol Res Perspect</i>. 2015;3(6):e00194. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27022468\">[PubMed 27022468]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2771":"<p><b>Title</b> DiazePAM / Metoclopramide</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Metoclopramide may increase the absorption of DiazePAM. This has only been documented with IV administration of metoclopramide. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> IV metoclopramide has been reported to increase peak serum concentrations of diazepam by approximately 38%, and the time to peak was reduced from 60-20 minutes.<sup>1</sup> Similar results were not found in a separate study using oral metoclopramide.<sup>2</sup> The mechanism for this potential interaction is unknown. The clinical significance is likely minimal.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gamble JA, Gaston JH, Nair SG, et al, “Some Pharmacological Factors Influencing the Absorption of Diazepam Following Oral Administration,” <i>Br J Anaesth</i>, 1976, 48(12):1181-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1023959\">[PubMed 1023959]</a></p>\n<p>2. Chapman MH, Woolner DF, Begg EJ, et al, “Coadministered Oral Metoclopramide Does Not Enhance the Rate of Absorption of Oral Diazepam,” <i>Anaesth Intensive Care</i>, 1988, 16(2):202-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3394914\">[PubMed 3394914]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2773":"<p><b>Title</b> Temazepam / Ondansetron</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Ondansetron does not appear to affect serum concentration of Temazepam. Nor does it appear to affect psychomotor performance. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 24 healthy volunteers, the co-administration of ondansetron 8 mg with temazepam 20 mg resulted in no change in the pharmacokinetics or pharmacodynamics (psychomotor performance) of temazepam.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Preston GC, Keene ON, Palmer JL. The effect of ondansetron on the pharmacokinetics and pharmacodynamics of temazepam. <i>Anaesthesia</i>. 1996;51(9):827-830. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8882243\">[PubMed 8882243]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2774":"<p><b>Title</b> Tricyclic Antidepressants / Altretamine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Altretamine may enhance the orthostatic hypotensive effect of Tricyclic Antidepressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for tricyclic antidepressant-induced orthostatic hypotension if altretamine is initiated or the dose is increased. Nortriptyline may be a safer alternative, as it possesses less hypotension potential.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline*, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine*, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Severe orthostatic hypotension has been reported in elderly patients receiving concomitant tricyclic antidepressants (specifically imipramine or amitriptyline) and altretamine. Effects were accompanied by dizziness, lightheadedness, and fainting.<sup>1</sup> Amitriptyline was started in place of imipramine in one patient without further incident. The mechanism of action is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bruckner HW and Schleifer SJ, “Orthostatic Hypotension as a Complication of Hexamethylmelamine Antidepressant Interaction,” <i>Cancer Treat Rep</i>, 1983, 67(5):516. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6406063\">[PubMed 6406063]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2775":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Altretamine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Altretamine may enhance the orthostatic hypotensive effect of Monoamine Oxidase Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for monoamine oxidase inhibitor-induced orthostatic hypotension if altretamine is initiated or the dose is increased. In general, furazolidone, linezolid, and procarbazine will pose less risk than isocarboxazid, phenelzine, or tranylcypromine. Caution is still advised. Selegiline administered in high oral dosages (eg, &gt;10 mg daily of tablet/capsule; &gt; 2.5 mg daily of orally disintegrating tablet) or transdermally will exhibit nonselective MAOI activity.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Methylene Blue, Moclobemide, Phenelzine*, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tranylcypromine<br><b>Exceptions</b> Linezolid, Tedizolid</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Severe orthostatic hypotension has been reported in elderly patients receiving concomitant monoamine oxidase inhibitors (specifically phenelzine) and altretamine. Effects were accompanied by dizziness, lightheadedness, and fainting.<sup>1</sup> The mechanism of action is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bruckner HW and Schleifer SJ, “Orthostatic Hypotension as a Complication of Hexamethylmelamine Antidepressant Interaction,” <i>Cancer Treat Rep</i>, 1983, 67(5):516.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2776":"<p><b>Title</b> Altretamine / Pyridoxine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Pyridoxine may diminish the therapeutic effect of Altretamine. Specifically when altretamine is used in combination with Cisplatin the response duration may be diminished. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> In spite of its beneficial effects on altretamine-associated neurotoxicity, the potential reduction in response duration may warrant consideration of not using pyridoxine in an altretamine/cisplatin regimen.</p> \n<p><b>Discussion</b> An Eastern Cooperative Oncology Group (ECOG) study in 248 patients receiving altretamine and cisplatin for ovarian carcinoma showed both positive and negative effects of adding pyridoxine to the regimen. Pyridoxine use was associated with a significant reduction in neurotoxicity, but concurrent pyridoxine was also one of several factors identified as having an adverse effect on clinical response duration.<sup>1</sup> The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wiernik PH, Yeap B, Vogl SE, et al, “Hexamethylmelamine and Low or Moderate Dose Cisplatin With or Without Pyridoxine for Treatment of Advanced Ovarian Carcinoma: A Study of the Eastern Cooperative Oncology Group,” <i>Cancer Invest</i>, 1992, 10(1):1-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1735009\">[PubMed 1735009]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2777":"<p><b>Title</b> Quinolones / Antacids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of quinolone antibiotics are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the absorption of Quinolones. Of concern only with oral administration of quinolones. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Avoid concurrent administration of quinolones and antacids to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone. Levofloxacin, norfloxacin, nalidixic acid, ofloxacin, and pipemidic acid should be administered at least 2 hours before or 2 hours after administration of an antacid. Ciprofloxacin and delafloxacin should be administered at least 2 hours before or 6 hours after administration of an antacid. Moxifloxacin should be administered at least 4 hours before or 8 hours after administration of an antacid. Gemifloxacin should be administered at least 3 hours before or 2 hours after administration of an antacid. Lomefloxacin should be administered at least 4 hours before or 2 hours after administration of an antacid. Sparfloxacin and pefloxacin should be administered at least 4 hours before or 4 hours after administration of an antacid. Consideration might also be given to the use of alternative, noninteracting acid reducers, such as histamine H2-antagonists. Monitor for decreased therapeutic effects of oral quinolones if administered with antacids.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Calcium Carbonate*, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide*, Magnesium Trisilicate, Potassium Bicarbonate<br><b>Exception</b> Sodium Bicarbonate</p>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Systemic), Lomefloxacin*, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin*, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin*<br><b>Exception</b> LevoFLOXacin (Oral Inhalation)</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The ability of antacids to reduce the absorption of oral quinolones is well-established. It is believed that the 3-carbonyl and 4-oxo functional groups on the antibiotic forms a chelate with the cations of the antacid resulting in inactive antimicrobials.<sup>1,2</sup> This interaction appears most significant with aluminum and magnesium ions, to a lesser extent with calcium ions, and probably nonexistent with sodium ions. The reduction in quinolone absorption can significantly affect Cmax and percent bioavailability, at times inhibiting the therapeutic effectiveness of the antibiotic. The quinolones vary in both the extent affected by the antacids (including the stability of the chelate).<sup>3</sup> Aluminum-magnesium antacids have been reported to reduce quinolone bioavailability by the following percentages: Ciprofloxacin (87%); levofloxacin (45%); lomefloxacin (49%); moxifloxacin (40%); norfloxacin (97%); ofloxacin (69%); and sparfloxacin (35%).<sup>4,5,6,7,8</sup> Calcium-containing antacids have been reported to reduce quinolone bioavailability by the following percentages: Ciprofloxacin (41%); levofloxacin (3%); lomefloxacin (2%); and norfloxacin (63%).<sup>7,9,10,11,12</sup> Calcium administration appears to affect the rate, but not the extent, of moxifloxacin absorption.<sup>12</sup><br><br>Abiding by the above recommended administration times should minimize the impact of any likely interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hoffken G, Borner K, Glatzel PD, et al. Reduced enteral absorption of ciprofloxacin in the presence of antacids. <i>Eur J Clin Microbiol</i>. 1985;4(3):345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3160584\">[PubMed 3160584]</a></p>\n<p>2. Shimada J, Shiba K, Oguma T, et al. Effect of antacid on absorption of the quinolone lomefloxacin. <i>Antimicrob Agents Chemother</i>. 1992;36(6):1219-1224. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1329615\">[PubMed 1329615]</a></p>\n<p>3. Mizuki Y, Fujiwara I, Yamaguchi T. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. <i>J Antimicrob Chemother</i>. 1996;37(Suppl A):41-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8737124\">[PubMed 8737124]</a></p>\n<p>4. Nix DE, Watson WA, Lener ME, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. <i>Clin Pharmacol Ther</i>. 1989;46(6):700-705. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2598571\">[PubMed 2598571]</a></p>\n<p>5. Shiba K, Sakamoto M, Nakazawa Y, et al. Effects of antacid on absorption and excretion of new quinolones. <i>Drugs</i>. 1995;49(Suppl 2):360-361. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8549362\">[PubMed 8549362]</a></p>\n<p>6. Shiba K, Sakai O, Shimada J, et al. Effects of antacids, ferrous sulfate and ranitidine on absorption of DR-3355 in humans. <i>Antimicrob Agents Chemother</i>. 1992;36(10):2270-2274. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1444308\">[PubMed 1444308]</a></p>\n<p>7. Stass H, Bottcher MF, Ochmann K. Evaluation of the influence of antacids and H2-antagonists on the absorption of moxifloxacin after oral administration of a 400 mg dose to healthy volunteers. <i>Clin Pharmacokinet</i>. 2001;40(Suppl 1):39-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11352441\">[PubMed 11352441]</a></p>\n<p>8. Frost RW, Lasseter KC, Noe AJ, et al. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. <i>Antimicrob Agents Chemother</i>. 1992;36(4):830-832. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1503446\">[PubMed 1503446]</a></p>\n<p>9. Lehto PL, Kivisto KT. Different effects of products containing metal ions on the absorption of lomefloxacin. <i>Clin Pharmacol Ther</i>. 1994;56(5):477-482. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7955811\">[PubMed 7955811]</a></p>\n<p>10. Nix DE, Wilton JH, Ronald B, et al. Inhibition of norfloxacin absorption by antacids. <i>Antimicrob Agents Chemother</i>. 1990;34(3):432-435. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2334155\">[PubMed 2334155]</a></p>\n<p>11. Sahai J, Healy DP, Stotka J, et al. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. <i>Br J Clin Pharmacol</i>. 1993;35(3):302-304. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8471407\">[PubMed 8471407]</a></p>\n<p>12. Stass H, Wandel C, Delesen H, et al. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers. <i>Clin Pharmacokinet</i>. 2001;40(Suppl 1):27-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11352439\">[PubMed 11352439]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2779":"<p><b>Title</b> Salicylates / Antacids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Duration</b>: Patients taking long-term, low-dose aspirin for prevention of cardiovascular events are likely at highest risk for a significant interaction with long-term concurrent use of antacids. Short-term antacid therapy and/or use of higher salicylate doses may be associated with a less significant interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Salicylates. <b>Severity</b> Minor <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of salicylates if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased. This interaction should not be of concern in patients receiving intermittent doses of salicylates.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide*, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate*</p>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin*, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Antacids, via their ability to produce a more alkaline urine, can increase the urinary excretion of salicylates. The resulting serum concentration of the salicylate can be subtherapeutic.<sup>1,2,3</sup> The salicylates, as acidic compounds, exist in an ionized form when in alkaline environments (as induced by antacids). This form of the compound is not easily reabsorbed in the kidney and is thus eliminated in the urine. The urinary excretion of aspirin has been shown to be significantly correlated with urinary pH, with increased excretion associated with increases in urine pH.<sup>4</sup><br><br>Antacids may also have an additional effect on enteric-coated salicylate products by altering the release of the active ingredient, further reducing the bioavailability of the product.<sup>5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Levy G, Lampman T, Kamath BL, et al, “Decreased Serum Salicylate Concentrations in Children with Rheumatic Fever Treated with Antacid,” <i>N Engl J Med</i>, 1975, 293(7):323-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=239345\">[PubMed 239345]</a></p>\n<p>2. Hansten PD and Hayton WL, “Effect of Antacid and Ascorbic Acid on Serum Salicylate Concentration,” <i>J Clin Pharmacol</i>, 1980, 20(5-6 Pt 1):326-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7400368\">[PubMed 7400368]</a></p>\n<p>3. Macpherson CR, Milne MD, and Evans BM, “The Excretion of Salicylate,” <i>Br J Pharmacol Chemother</i>, 1955, 10(4):484-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13276608\">[PubMed 13276608]</a></p>\n<p>4. Elliot Cham B, Dykman JH, Bochner F, “Urinary Excretion of Aspirin,” <i>Br J Clin Pharmacol</i>, 1982, 14(4):562-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7138740\">[PubMed 7138740]</a></p>\n<p>5. Feldman S and Carlstedt BC, “Effect of Antacid on Absorption of Enteric-Coated Aspirin,” <i>JAMA</i>, 1974, 227(6):660-1 (letter). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4405837\">[PubMed 4405837]</a></p>\n<p>6. Strickland-Hodge B, Thomas TR, Gould WA, et al, “The Effects of Antacids on Enteric-Coated Salicylate Preparations,” <i>Rheumatol Rehabil</i>, 1976, 15(3):148-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=968338\">[PubMed 968338]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2783":"<p><b>Title</b> Tetracyclines / Antacids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of tetracycline antibiotics are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the absorption of Tetracyclines. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Separate administration of antacids and oral tetracycline derivatives by several hourse when possible to minimize the extent of this potential interaction. Consider using an alternative acid-reducing agent in place of the antacid when possible. Monitor for decreased therapeutic effects of tetracyclines if this combination is used.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Calcium Carbonate*, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide*, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate*</p>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline*, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The ability of antacids to significantly reduce the absorption of tetracyclines, possibly resulting in subtherapeutic serum antibiotic concentrations, is well-established.<sup>1,2,3,4,5,6,7,8,9,10</sup> In a study summarized in the demeclocycline package insert, coadministration with antacids containing aluminum, calcium, or magnesium decreased the extent of demeclocycline absorption by more than 50%.<sup>4</sup> Further studies confirm these findings, reporting more than 80% reduction in oral bioavailability of tetracycline, doxycycline, and demeclocycline when magnesium-aluminum hydroxide was coadministered in healthy volunteers.<sup>5,6,7,8</sup> One study also observed a decrease in the AUC of intravenously administered doxycycline when coadministered with aluminum hydroxide.<sup>9</sup> Furthermore, sodium bicarbonate coadministration with tetracycline decreased the extent of absorption by 50% in one study with healthy volunteers,<sup>10</sup> while in another study there was no reported change in the oral bioavailability of tetracycline.<sup>6</sup><br><br>There may be more than one mechanism responsible for the observed interactions depending on the specific antacid used. One possible mechanism is the formation of chelates between oral tetracyclines and aluminum, bismuth, calcium, and magnesium.<sup>8</sup> Such chelates have reduced solubility and thus reduced absorption from the GI tract. Additionally, tetracycline solubility may be reduced in more alkaline environments (such as that produced by antacids) and, thus, absorption may be reduced.<sup>10</sup> This may specifically explain the effect of sodium bicarbonate on oral tetracyclines. It has also been proposed that alkalinization of the urine may increase doxycycline clearance, suggesting a possible mechanism for the interaction seen with intravenous doxycycline.<sup>9,11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Scheiner J, Altemeier WA. Experimental study of factors inhibiting absorption and effective therapeutic levels of declomycin. <i>Surg Gynecol Obstet</i>. 1962;114:9-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14498173\">[PubMed 14498173]</a></p>\n<p>2. Albert KS, Welch RD, DeSante KA, et al. Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture. <i>J Pharm Sci</i>. 1979;68(5):586-588. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=435335\">[PubMed 435335]</a></p>\n<p>3. Ericsson CD, Feldman S, Pickering LK, et al. Influence of subsalicylate bismuth on absorption of doxycycline. <i>JAMA</i>. 1982;247(16):2266-2267. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7040708\">[PubMed 7040708]</a> </p>\n<p>4. Demeclocycline [prescribing information]. Paterson, NJ: Amneal Pharmaceuticals; March 2017.</p>\n<p>5. Rosenblatt JE, Barrett JE, Brodie JL, et al. Comparison on in vitro activity and clinical pharmacology of doxycycline with other tetracyclines. <i>Antimicrob Agents Chemother</i>. 1966;6:134-141. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4964450\">[PubMed 4964450]</a></p>\n<p>6. Garty M, Hurwitz A. Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline. <i>Clin Pharmacol Ther</i>. 1980;28(2):203-207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7398187\">[PubMed 7398187]</a></p>\n<p>7. Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. <i>Antimicrob Agents Chemother</i>. 1989;33(11):1901-1907. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2610502\">[PubMed 2610502]</a></p>\n<p>8. Ogawa R, Echizen H. Clinically significant drug interactions with antacids: an update. <i>Drugs</i>. 2011;71(14):1839-1864. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21942976\">[PubMed 21942976]</a></p>\n<p>9. Nguyen VX, Nix DE, Gillikin S, Schentag JJ. Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline. <i>Antimicrob Agents Chemother</i>. 1989;33(4):434-436. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2729939\">[PubMed 2729939]</a></p>\n<p>10. Barr WH, Adir J, Garrettson L. Decrease of tetracycline absorption in man by sodium bicarbonate. <i>Clin Pharmacol Ther</i>. 1971;12(5):779-784. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4936141\">[PubMed 4936141]</a></p>\n<p>11. Jaffe JM, Poust RI, Feld SL, et al. Influence of repetitive dosing and altered urinary pH on doxycycline excretion in humans. <i>J Pharm Sci</i>. 1974;63(8):1256-1260. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4852448\">[PubMed 4852448]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2784":"<p><b>Title</b> Histamine H2 Receptor Antagonists / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Histamine H2 Receptor Antagonists. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide*, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine*, Famotidine*, Lafutidine, Nizatidine, RaNITIdine*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Studies have produced variable results regarding the effect of antacids on histamine H<sub>2</sub>-antagonist absorption. AUC reductions from zero to 59% have been reported with cimetidine, famotidine, and ranitidine.<sup>1,2,3,4,5,6,7,8,9</sup> According to one comparative study, the interaction between antacids and histamine H2-antagonists seems to be greater with cimetidine and ranitidine compared to famotidine and nizatidine.<sup>10</sup> No clinically significant impact on the therapeutic efficacy of the histamine H<sub>2</sub>-antagonist has been noted. The mechanism of these interactions is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shelly DW, Doering PL, Russell WL, et al. Effect of concomitant antacid administration on plasma cimetidine concentrations during repetitive dosing. <i>Drug Intell Clin Pharm</i>. 1986;20(10):792-795. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3769772\">[PubMed 3769772]</a></p>\n<p>2. Burland WL, Darkin DW, Mills MW. Effect of antacids on absorption of cimetidine. <i>Lancet</i>. 1976;2(7992):965. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=62195\">[PubMed 62195]</a></p>\n<p>3. Bodemar G, Norlander B, Walan A. Diminished absorption of cimetidine caused by antacids. <i>Lancet</i>. 1979;1(8113):444-445. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=84296\">[PubMed 84296]</a></p>\n<p>4. Steinberg WM, Lewis JH, Katz DM. Antacids inhibit absorption of cimetidine. <i>N Engl J Med</i>. 1982;307(7):400-404. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=708843\">[PubMed 708843]</a></p>\n<p>5. Barzaghi N, Gatti G, Crema F, et al. Impaired bioavailability of famotidine given concurrently with a potent antacid. <i>J Clin Pharmacol</i>. 1989;29(7):670-672. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2569486\">[PubMed 2569486]</a></p>\n<p>6. Lin JH, Chremos AN, Kanovsky SM, et al. Effects of antacids and food on absorption of famotidine. <i>Br J Clin Pharmacol</i>. 1987;24(4):551-553. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2891370\">[PubMed 2891370]</a></p>\n<p>7. Mihaly GW, Marino AT, Webster LK, et al. High dose of antacid (Mylanta II) reduces the bioavailability of ranitidine. <i>Br Med J</i>. 1982;285(6347):998-999. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6289961\">[PubMed 6289961]</a></p>\n<p>8. Desmond PV, Harman PJ, Gannoulis N, et al. The effect of an antacid and food on the absorption of cimetidine and ranitidine. <i>J Pharm Pharmacol</i>. 1990;42(5):352-354. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1976784\">[PubMed 1976784]</a></p>\n<p>9. Donn KH, Eshelman FN, Plachetka JR, et al. The effects of antacid and propantheline on the absorption of oral ranitidine. <i>Pharmacotherapy</i>. 1984;4(2):89-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6326064\">[PubMed 6326064]</a></p>\n<p>10. Sullivan TJ, Reese JH, Jauregui L, Miller K, Levine L, Bachmann KA. Short report: a comparative study of the interaction between antacid and H2-receptor antagonists. <i>Aliment Pharmacol Ther</i>. 1994;8(1):123-126. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7910488\">[PubMed 7910488]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2785":"<p><b>Title</b> Antipsychotic Agents (Phenothiazines) / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines). <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of phenothiazines if an antacid is administered concurrently. If decreased effects are noted, consider separating doses of agents by 2 or more hours in order to minimize potential adsorption of the phenothiazine onto the antacid.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n <p><b>Antipsychotic Agents (Phenothiazines) Interacting Members</b> ChlorproMAZINE*, FluPHENAZine, Methotrimeprazine, Periciazine, Perphenazine, Pipotiazine, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Coadministration of chlorpromazine and aluminum hydroxide has reduced serum chlorpromazine concentrations by 20%.<sup>1</sup> Another study using chlorpromazine and an antacid containing aluminum hydroxide and magnesium trisilicate showed urinary chlorpromazine excretion was reduced by 10% to 45%.<sup>2</sup> In vitro data demonstrates adsorption of various phenothiazines (fluphenazine, perphenazine, thioridazine, and trifluperazine) onto various antacids (aluminum hydroxide-magnesium carbonate, bismuth subnitrate, and magnesium trisilicate).<sup>3</sup> Definitive information regarding the mechanism of these interactions is lacking.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fann WE, Davis JM, Janowsky DS, et al, “Chlorpromazine: Effects of Antacids on its Gastrointestinal Absorption,” <i>J Clin Pharmacol</i>, 1973, 13(10):388-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4355737\">[PubMed 4355737]</a></p>\n<p>2. Forrest FM, Forrest IS, and Serra MT, “Modification of Chlorpromazine Metabolism by Some Other Drugs Frequently Administered to Psychiatric Patients,” <i>Biol Psychiatry</i>, 1970, 2(1):53-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5414905\">[PubMed 5414905]</a></p>\n<p>3. Moustafa MA, Babhair SA, and Kouta HI, “Decreased Bioavailability of Some Antipsychotic Phenothiazines Due to Interactions With Absorbent Antacid and Antidiarrhoeal Mixtures,” <i>Int J Pharm</i>, 1987, 36:185-9.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2786":"<p><b>Title</b> Aluminum Hydroxide / Ascorbic Acid</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Renal Function</b>: The clinical significance of this interaction is likely of much greater significance in patients with impaired renal function.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ascorbic Acid may increase the absorption of Aluminum Hydroxide. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> In patients with severe renal dysfunction, consider avoiding this combination of agents. Administering agents at least 2 hours apart may help minimize effects. Monitor for toxic effects of aluminum (from antacid) if ascorbic acid is coadministered.</p> \n<p><b>Discussion</b> A small study demonstrated a threefold increase in urinary aluminum excretion when subjects received concomitant aluminum hydroxide (900 mg 3 times/day) and vitamin C (2 g/day).<sup>1</sup> Animal studies have demonstrated increased aluminum concentrations in the liver, brains, and bones of rats given aluminum hydroxide and vitamin C.<sup>2</sup> The mechanism of this interaction is unknown, but has been suggested to be related to the formation of a soluble aluminum-citrate complex.<sup>3</sup> Significant clinical effects have been reported with concomitant aluminum hydroxide and oral citrate product administration in patients with severe renal dysfunction.<sup>4,5,6</sup> Though reports of negative clinical outcomes with ascorbic acid have not been noted, caution should, nevertheless, be exercised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Domingo JL, Gomez M, Llobet JM, et al, “Effect of Ascorbic Acid on Gastrointestinal Aluminum Absorption,” <i>Lancet</i>, 1991, 338(8780):1467. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1683458\">[PubMed 1683458]</a></p>\n<p>2. Domingo JL, Gomez M, Llobet JM, et al, “Influence of Some Dietary Constituents on Aluminum Absorption and Retention in Rats,” <i>Kidney Int</i>, 1991, 39(4):598-601. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2051716\">[PubMed 2051716]</a></p>\n<p>3. Coburn JW, Mischel MG, Goodman WG, et al, “Calcium Citrate Markedly Enhances Aluminum Absorption From Aluminum Hydroxide,” <i>Am J Kid Dis</i>, 1991, 17(6):708-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2042654\">[PubMed 2042654]</a></p>\n<p>4. Kirschbaum BB and Schoolwerth AC, “Acute Aluminum Toxicity Associated With Oral Citrate and Aluminum-Containing Antacids,” <i>Am J Med Sci</i>, 1989, 297(1):9-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2913801\">[PubMed 2913801]</a></p>\n<p>5. Main J and Ward MK, “Potentiation of Aluminum Absorption by Effervescent Analgesic Tablets in a Haemodialysis Patient,” <i>Br Med J</i>, 1992, 304(6843):1686. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1633526\">[PubMed 1633526]</a></p>\n<p>6. Bakir AA, Hryhorczuk DO, Ahmed S, et al, “Hyperaluminemia in Renal Failure: The Influence of Age and Citrate Intake,” <i>Clin Nephrol</i>, 1989, 31(1):40-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2914409\">[PubMed 2914409]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2787":"<p><b>Title</b> Aluminum Hydroxide / Citric Acid Derivatives</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Renal Function</b>: The clinical significance of this interaction is likely of much greater significance in patients with impaired renal function.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> In patients with severe renal dysfunction, consider avoiding this combination of agents. Administering agents at least 2 hours apart may help minimize effects in patients without renal dysfunction. Monitor for toxic effects of aluminum if citric acid is coadministered.</p>\n<div>\n <p><b>Citric Acid Derivatives Interacting Members</b> Calcium Citrate, Citric Acid, Magnesium Citrate, Potassium Citrate, Sodium Citrate</p>\n</div> \n<p><b>Discussion</b> Several cases of patients with renal failure experiencing significant adverse CNS events following concomitant administration of oral citrates and aluminum hydroxide have been reported.<sup>1,2</sup> These events have included confusion, myoclonus, seizures, coma, and death. Marked elevations in serum aluminum concentrations were noted in some patients. Another patient experienced a 10-fold increase in serum aluminum concentrations when administered an aluminum-containing antacid and an effervescent formulation of codamol. The effervescing agent was sodium citrate.<sup>3</sup> Several studies have similarly reported significantly elevated serum aluminum associated with the administration of citrate- or citric acid-containing products.<sup>4,5,6,7,8</sup> This has been observed in hemodialysis patients, patients with renal failure, and healthy volunteers.<br><br>The mechanism of this interaction is unknown, but has been suggested to be related to the formation of a soluble aluminum-citrate complex.<sup>9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kirschbaum BB, Schoolwerth AC. Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. <i>Am J Med Sci</i>. 1989;297(1):9-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2913801\">[PubMed 2913801]</a></p>\n<p>2. Bakir AA, Hryhorczuk DO, Ahmed S, et al. Hyperaluminemia in renal failure: the influence of age and citrate intake. <i>Clin Nephrol</i>. 1989;31(1):40-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2914409\">[PubMed 2914409]</a></p>\n<p>3. Main J, Ward MK. Potentiation of aluminium absorption by effervescent analgesic tablets in a haemodialysis patient. <i>BMJ</i>. 1992;304(6843):1686. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1633526\">[PubMed 1633526]</a></p>\n<p>4. Nolan CR, DeGoes JJ, Alfrey AC. Aluminum and lead absorption from dietary sources in women ingesting calcium citrate. <i>South Med J</i>. 1994;87(9):894-898. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8091252\">[PubMed 8091252]</a></p>\n<p>5. Fairweather-Tait S, Hickson K, McGaw B, Reid M. Orange juice enhances aluminium absorption from antacid preparation. <i>Eur J Clin Nutr</i>. 1994;48(1):71-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8200332\">[PubMed 8200332]</a></p>\n<p>6. Nestel AW, Meyers AM, Paiker J, Rollin HB. Effect of calcium supplement preparation containing small amounts of citrate on the absorption of aluminium in normal subjects and in renal failure patients. <i>Nephron</i>. 1994;68(2):197-201. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7830856\">[PubMed 7830856]</a></p>\n<p>7. Lindberg JS, Copley JB, Koenig KG, Cushner HM. Effect of citrate on serum aluminum concentrations in hemodialysis patients: a prospective study. <i>South Med J</i>. 1993;86(12):1385-1388. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8272917\">[PubMed 8272917]</a></p>\n<p>8. Rudy D, Sica DA, Comstock T, Davis J, Savory J, Schoolwerth AC. Aluminum-citrate interaction in end-stage renal disease. <i>Int J Artif Organs</i>. 1991;14(10):625-629. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1748529\">[PubMed 1748529]</a></p>\n<p>9. Coburn JW, Mischel MG, Goodman WG, Salusky IB. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. <i>Am J Kidney Dis</i>. 1991;17(6):708-711. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2042654\">[PubMed 2042654]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2788":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antacids may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide*, Magnesium Trisilicate, Potassium Bicarbonate<br><b>Exceptions</b> Calcium Carbonate, Sodium Bicarbonate</p>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal*, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen*, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen*, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Aluminum/magnesium hydroxide-containing antacids have been reported to decrease the absorption of various nonsteroidal anti-inflammatory agents (NSAID). Ketoprofen absorption was decreased by 22% when coadministered with aluminum hydroxide.<sup>1</sup> A small study showed an 11% reduction in ketorolac absorption when coadministered with aluminum/magnesium hydroxide.<sup>2</sup> Diflunisal bioavailability has been reduced by approximately 30% when coadministered with aluminum/magnesium hydroxide.<sup>3,4</sup> The rate of absorption (but not necessarily the extent) of naproxen was reportedly decreased by aluminum hydroxide and magnesium oxide, whereas aluminum/magnesium hydroxide appeared to not affect naproxen absorption.<sup>5</sup> Celecoxib appears to be minimally affected by aluminum- and magnesium-containing antacids,<sup>6</sup> and nambumetone serum concentrations appears to be unaffected by aluminum hydroxide.<sup>7</sup> The mechanism of these interactions is likely due to adsorption of the NSAID onto the antacid. There are no reports of negative clinical outcomes related to these interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ismail FA, Khalafallah N, and Khalil SA, “Absorption of Ketoprofen and Bumadizone Calcium on Aluminum-Containing Antacids and Its Effect on Ketoprofen Bioavailability in Man,” <i>Int J Pharm</i>, 1987, 34:189-96.</p>\n<p>2. Mroszczak EJ, Jung D, Yee J, et al, “Ketorolac Tromethamine Pharmacokinetics and Metabolism After Intravenous, Intramuscular, and Oral Administration in Humans and Animals,” <i>Pharmacotherapy</i>, 1990, 10(6 Pt 2):33S-9S (review). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2082311\">[PubMed 2082311]</a></p>\n<p>3. Holmes GI, et al, “Effects of Maalox on the Bioavailability of Diflunisal,” <i>Clin Pharmacol Ther</i>, 1979, 25:229.</p>\n<p>4. Verbeeck R, Tjandramaga TB, Mullie A, et al, “Effect of Aluminum Hydroxide on Diflunisal Absorption,” <i>Br J Clin Pharmacol</i>, 1979, 7(5):519-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=314299\">[PubMed 314299]</a></p>\n<p>5. Segre EJ, Sevelium H, and Varady J, “Effects of Antacids on Naproxen Absorption, ” <i>N Engl J Med</i>, 1974, 291(11):582-3 (letter). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4852768\">[PubMed 4852768]</a></p>\n<p>6. Prescribing information. Celebrex (celecoxib). New York, NY: Pfizer Inc, January 2011.</p>\n<p>7. von Schrader HW, Buscher G, Dierdorf D, et al, “Nabumetone - A Novel Anti-Inflammatory Drug: The Influence of Food, Milk, Antacids, and Analgesics on Bioavailability of Single Oral Doses,” <i>Int J Clin Pharmacol Ther Tox</i>, 1983, 21(6):311-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6688407\">[PubMed 6688407]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2789":"<p><b>Title</b> Vitamin K Antagonists / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Antacids do not appear to affect serum concentration of Vitamin K Antagonists. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide*, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Warfarin serum concentrations appeared unaffected when coadministered with aluminum/magnesium hydroxide or aluminum hydroxide.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ambre JJ and Fischer LJ, “Effect of Coadministration of Aluminum and Magnesium Hydroxides on Absorption of Anticoagulants in Man,” <i>Clin Pharmacol Ther</i>, 1973, 14(2):231-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4121122\">[PubMed 4121122]</a></p>\n<p>2. Robinson DS, Benjamin DM, and McCormack JJ, “Interaction of Warfarin and Nonsystemic Gastrointestinal Drugs,” <i>Clin Pharmacol Ther</i>, 1971, 12(3):491-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5567801\">[PubMed 5567801]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2790":"<p><b>Title</b> Cardiac Glycosides / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Cardiac Glycosides. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide*, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In one pharmacokinetic study of 10 healthy volunteers, the AUC of digoxin (0.75 mg single dose) was reduced 38% along with a decrease of 29% in the digoxin 6-day cumulative urinary excretion after coadministration with magnesium trisilicate (60 mL single dose).<sup>1</sup> The AUC of digoxin was reduced 26% and 25%, respectively, by single doses of aluminum hydroxide (60 mL of a 4% gel) and magnesium hydroxide (60 mL of an 8% gel), but neither change reached statistical significance.<sup>1</sup> In another study of 12 healthy volunteers, administration of a single dose of aluminum hydroxide and magnesium hydroxide (45 mg and 40 mg) decreased the maximum serum concentration (Cmax) of digoxin capsules (0.4 mg) by 34%, but had no effect on the Cmax of digoxin tablets (0.4 mg).<sup>2</sup> No change in digoxin AUC was noted with either formulation. In a letter to the editor, it was reported that administration of aluminum hydroxide (10 mL three times daily for 7 days) or magnesium trisilicate (10 mL three times daily for 7 days) had no effect of the bioavailability of digoxin (0.25 to 0.5 mg) in 4 patients.<sup>3</sup><br><br>Adsorption of digoxin onto the antacid, reducing digoxin absorption, may be a mechanism for these interactions. The clinical relevance of this data is uncertain, as the magnitude of the pharmacokinetic changes appears small and may be of concern only with magnesium trisilicate containing products.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brown DD, Juhl RP. Decreased bioavailability of digoxin due to antacids and kaolin-pectin. <i>N Engl J Med</i>. 1976;295(19):1034-1037. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=972657\">[PubMed 972657]</a></p>\n<p>2. Allen MD, Greenblatt DJ, Harmatz JS, Smith TW. Effect of magnesium-aluminum hydroxide and kaolin-pectin on absorption of digoxin from tablets and capsules. <i>J Clin Pharmacol</i>. 1981;21(1):26-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7012189\">[PubMed 7012189]</a></p>\n<p>3. Cooke J, Smith JA. Absence of interaction of digoxin with antacids under clinical conditions. <i>Br Med J</i>. 1978;2(6145):1166-1167. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=709293\">[PubMed 709293]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2792":"<p><b>Title</b> Iron Salts / Antacids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of iron salts are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the absorption of Iron Salts. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Separate dosing of oral iron preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation. Monitor for decreased therapeutic effects of oral iron preparations if an antacid is coadministered.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Calcium Carbonate*, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate*</p>\n <p><b>Iron Salts Interacting Members</b> Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate*, Iron Acetyltransferrin, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exceptions</b> Ferric Carboxymaltose, Ferric Citrate, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferumoxytol, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Iron absorption was decreased an average of 60% when given as ferrous sulfate and coadministered with magnesium trisilicate.<sup>1</sup> Sodium bicarbonate and calcium carbonate have had similar effects on ferrous sulfate.<sup>2,3</sup> The effects of aluminum hydroxide are probably similar to other antacids.<sup>2,4</sup> The proposed mechanisms for these interactions vary according to the interacting antacid. Carbonate products might form less soluble iron complexes.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hall GJ and Davis AE, “Inhibition of Iron Absorption by Magnesium Trisilicate,” <i>Med J Aust</i>, 1969, 2(2):95-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5803866\">[PubMed 5803866]</a></p>\n<p>2. O’Neil-Cutting MA and Crosby WH, “The Effect of Antacids on the Absorption of Simultaneously Ingested Iron,” <i>JAMA</i>, 1986, 255(11):1468-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3005669\">[PubMed 3005669]</a></p>\n<p>3. Benjamin IB, Cortell S, and Conrad ME, “Bicarbonate-Induced Iron Complexes and Iron Absorption,” <i>Gastroenterology</i>, 1967, 35:389.</p>\n<p>4. Coste JF, De Bari VA, Keil LB, et al, “<i>In vitro</i> Interactions of Oral Haematinics and Antacid Preparations,” <i>Curr Ther Res Clin Exp</i>, 1977, 22:205.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2793":"<p><b>Title</b> Flucytosine / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antacids may decrease the absorption of Flucytosine. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide*, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Aluminum/magnesium hydroxide is reported to decrease the rate, but not the extent, of flucytosine absorption.<sup>1</sup> The mechanism is unclear. No indication of negative patient outcomes is available.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cutler RE, Blair AD, and Kelly MR, “Flucytosine Kinetics in Subjects With Normal and Impaired Renal Function,” <i>Clin Pharmacol Ther</i>, 1978, 24:333-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=688726\">[PubMed 688726]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2794":"<p><b>Title</b> Sulfonylureas / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antacids may increase the absorption of Sulfonylureas. Increase in rate, not extent. <b>Severity</b> Minor <b>Onset</b> Rapid <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> No action needed.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide*, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate*</p>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE*, Gliclazide, Glimepiride, GlipiZIDE*, GlyBURIDE*, TOLAZamide, TOLBUTamide*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Most reports describe increases in the rate, but not the extent, of absorption of sulfonylureas when coadministered with antacids.<sup>1,2,3,4,5,6,7</sup> One study observed that coadministration of magnesium hydroxide with tolbutamide increased the tolbutamide AUC (0-1 hour) and AUC (0-2 hour) by 5- and 2.5-fold, respectively, but there was no significant increase in AUC (total).<sup>1</sup> In contrast, despite a trend towards accelerated absorption of chlorpropamide, there was no significant increase in any chlorpropamide AUC value with coadministration of magnesium hydroxide.<sup>1</sup> Other studies investigated antacid coadministration with glibenclamide observing an increase in rate of absorption and early bioavailability of non-micronized glibenclamide with both magnesium hydroxide and sodium bicarbonate.<sup>2,3,4</sup> In another study, coadministration of sodium bicarbonate with glipizide increased glipizide AUC (0-0.5 hour), AUC (0-1 hour), and AUC (0-2 hour) by 6-, 4-, and 2-fold, respectively, with no significant increase in AUC (total).<sup>5</sup> Similarly, magnesium hydroxide coadministration with glipizide increased the early bioavailability, but had no significant effect on extent of glipizide absorption.<sup>6</sup> In contrast, there was no significant effect on rate of absorption when glipizide was coadministered with aluminum hydroxide.<sup>5</sup> While some studies report brief increases in early plasma insulin concentrations, transient decreases in glucose concentrations have only been observed with tolbutamide/magnesium hydroxide, glipizide/sodium bicarbonate, and glipizide/magnesium hydroxide combinations.<sup>1,2,5,6</sup><br><br>Only one report has described an increase in the extent of absorption observing a 3-fold increase in AUC (total) with non-micronized glibenclamide and magnesium hydroxide coadministration, but no changes in glucose concentrations were reported in healthy volunteers.<sup>2</sup><br><br>The mechanism of these interactions is likely related to the increase in gastric pH caused by the antacids, which in turn increases the solubility and absorption of the sulfonylurea.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kivisto KT, Neuvonen PJ. Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide. <i>Eur J Clin Pharmacol</i>. 1992;42(6):675-679. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1623912\">[PubMed 1623912]</a></p>\n<p>2. Neuvonen PJ, Kivisto KT. The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations. <i>Br J Clin Pharmacol</i>. 1991;32(2):215-220. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1931470\">[PubMed 1931470]</a></p>\n<p>3. Zuccaro P, Pacifici R, Pichini S, et al. Influence of antacids on the bioavailability of glibenclamide. <i>Drugs Exp Clin Res</i>. 1989;15(4):165-169. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2505996\">[PubMed 2505996]</a></p>\n<p>4. Kivisto KT, Lehto P, Neuvonen PJ. The effects of different doses of sodium bicarbonate on the absorption and activity of nonmicronized glibenclamide. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1993;31(5):236-240. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8390970\">[PubMed 8390970]</a></p>\n<p>5. Kivisto KT, Neuvonen PJ. Differential effects of sodium bicarbonate and aluminum hydroxide on the absorption and activity of glipizide. <i>Eur J Clin Pharmacol</i>. 1991;40(4):383-386. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1646724\">[PubMed 1646724]</a></p>\n<p>6. Kivisto KT, Neuvonen PJ. Enhancement of absorption and effect of glipizide by magnesium hydroxide. <i>Clin Pharmacol Ther</i>. 1991;49(1):39-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1988239\">[PubMed 1988239]</a></p>\n<p>7. Ogawa R, Echizen H. Clinically significant drug interactions with antacids: an update. <i>Drugs</i>. 2011;71(14):1839-1864. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21942976\">[PubMed 21942976]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2796":"<p><b>Title</b> Lithium / Sodium Bicarbonate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sodium Bicarbonate may increase the excretion of Lithium. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of lithium if sodium bicarbonate is initiated/dose increased, or increased effects if sodium bicarbonate is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Ingestion of sodium bicarbonate (and other sodium-containing substances) has resulted in decreased serum lithium concentrations.<sup>1,2,3,4</sup> It appears that the renal proximal tubule treats lithium and sodium ions in a similar fashion, and thus when sodium concentrations are increased, both sodium and lithium ions are excreted. The converse would also be true. Aluminum/magnesium-containing antacids do not appear to affect lithium serum concentrations.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Thomsen K and Schou M, “Renal Lithium Excretion in Man,” <i>Am J Physiol</i>, 1968, 215(4):823-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5676383\">[PubMed 5676383]</a></p>\n<p>2. Bleiweiss H, “Salt Supplements With Lithium,” <i>Lancet</i>, 1970, 1(7643):416. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4189720\">[PubMed 4189720]</a></p>\n<p>3. Hurtig HI and Dyson WL, “Lithium Toxicity Enhanced by Diuresis,” <i>N Engl J Med</i>, 1974, 290(13):748-9 (letter). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4813752\">[PubMed 4813752]</a></p>\n<p>4. Corcoran AC, Taylor RD, and Page IH, “Lithium Poisoning From the Use of Salt Substitutes,” <i>JAMA</i>, 1949, 139:685. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18110875\">[PubMed 18110875]</a></p>\n<p>5. Goode DL, Newton DW, Ueda CT, et al, “Effect of Antacid on the Bioavailability of Lithium Carbonate,” <i>Clin Pharm</i>, 1984, 3(3):284-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6428800\">[PubMed 6428800]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}